Progress of finding latent therapeutic activity of vaccine for Alzheimer's disease

By

Md. Muhtaz Hassan

ID: 10246002

Department of Pharmacy
BRAC University
May, 2019

Declaration

It is hereby declared that

1. The project submitted is my own original work while completing Bachelor of Pharmacy at BRAC University.
2. The project does not contain material previously published or written by a third party, except where this is appropriately cited through full and accurate referencing.
3. The project does not contain material which has been accepted, or submitted, for any other degree or diploma at a university or other institution.
4. I have acknowledged all main sources of help.

Student's Full Name & Signature:

Student Full Name
Student ID

Approval

The project titled "Progress of finding latent therapeutic activity of vaccine for Alzheimer's disease" submitted by

1. Md. Muhtaz Hassan , ID: 10246002

Of Spring 2011, has been accepted as satisfactory in partial fulfillment of the requirement for

the degree of Bachelor of Pharmacy on 29th May.

Examining Committee:

Thesis Supervisor:

_____

Md. Tanvir Kabir
Senior Lecturer
Department of Pharmacy, BRAC University

Program Coordinator:

_____

Dr. Hasina Yasmin
Associate Professor, Department of Pharmacy
BRAC University

Departmental Chairperson:

_____

Prof. Dr. Eva Rahman Kabir
Chairperson, Department of Pharmacy
BRAC University

Ethics Statement

This is to certify that this project titled “Progress of finding latent therapeutic activity of vaccine for Alzheimer’s disease” is submitted for the partial fulfillment of the requirements for the degree of Bachelor of Pharmacy (Hons.) from the Department of Pharmacy, BRAC University constitutes my own work under supervision of Md. Tanvir Kabir, Senior Lecturer, Department of Pharmacy, BRAC University and I have given appropriate credit where I have used language, ideas or writings of another.

Abstract

Alzheimer's disease is one of leading diseases which provokes different internal physiological conditions that ease deterioration of normal body mechanism among people over 60 years of age. The proper pathophysiology of this disease is still undiscovered. There are two neuropathological hallmarks for this deadliest disease, among them one is amyloid-β and another is senile plaque deposition which plays extracellular role, on the other side neurofibrillary tangles which contain hyperphosphorylated tau protein dominate intracellular portion. A variety of medicinal approaches have been experimented targeting amyloid-β among them the most innovative approaches were reducing amyloid-β from the brain by active and passive vaccination. Since the first approach, a number of vaccines have been stopped during clinical trials and some are still under investigation. Different co-relating possibilities are merging together to initiate a proper medicinal pathway along with the invention of the specific pathophysiology of this disease.

Keywords: Alzheimer's disease, Amyloid-β, Neurofibrillary tangles, Senile plaque, Active vaccination, Passive vaccination

Dedication

Dedicated to the Chairperson of Department of Pharmacy, Prof. Dr. Eva Rahman Kabir and my supervisor Md. Tanvir Kabir

Acknowledgement

All honors belong to Allah for strengthening me with patience to complete my project work along with the courses necessary to complete Bachelor of Pharmacy (B.Pharm) program.

I am grateful to my respected supervisor, Md. Tanvir Kabir, Senior Lecturer, Department of Pharmacy, BRAC University for supporting me continuously and giving me the motivation to complete the project paper. Without his support it was not possible to finish my project work.

I am also grateful to Prof. Dr. Eva Rahman Kabir, Honorable Chairperson, Department of Pharmacy, and BRAC University for giving me the support and opportunity to complete my project work and B.Pharm program.

Table of Contents

List of Tables

List of Figures

List of Acronyms

AD	Alzheimer's Disease
SP	Senile plaque
NFT	Neurofibrillary tangles
CSF	Cerebrospinal fluid
Aβ	Amyloid Beta
APP	Amyloid precursor protein
CAA	Cerebral amyloid angiopathy
HSV	Herpis syndrome virus
AICD	Amyloid intracellular domain
PD	Pick disease
PSP	Progressive supranuclear palasy
MAP	Microtubule associated protein
PHF	Paired helical filament
PTM	Post transitional modification
MT	Microtubule

Chapter 1 Background

Dementia is a common term used for the problems related to declination of mental ability that have enough potential to interfere with normal life by reducing memory. The most operable cause of dementia is AD. AD is accountable for almost 60-80% of dementia. It is also termed as memory loss as well as other cognitive disorders which are capable of interfering memory loss. Initiation of AD depends on the accumulation of amyloid-β and tau-tangles in the brain (Davtyan et al., 2014). On the other side it is estimated that one person is getting affected by dementia every 3 second worldwide. There were an estimation of 4.68 crore human being who are affected with dementia and this value could rise to 5 crore by 2017. Another crucial data is almost 50% of these patients live in middle to lower income countries. Specific cause of AD is still not recognized, a Varity of factors are involved in the development process of this disease (Barrera-Ocampo & Lopera, 2016). The molecular pathology of this neurodegenerative disease is yet to be discovered. Neurological study finds that irregular production and extracellular deposition of longer amyloid-β plays a cricial function in the pathogenesis of AD (Close, We, & Janus, 2003).

Chapter 2 Global Impact of AD

Now-a-days, around 4.68 crore people are suffering from dementia globally. The overall calculation estimates that it will rise to 13.11 crore by 2050. The total estimated cost for dementia has turned to a trillion dollar which lays a great economic effect by 2018. People are getting aware throughout the world about the deadly disease but its treatment may cause stain and social isolation to the patient. In lower and middle income country 94% people are having treatment at home. The cost and trend of dementia will increase day by day, and will be the foremost challenge of public health and social care, to make sure of well being of dementia patient, national plans are required to equip the hospital to provide appropriate

treatment which will reduce risk as well as for the future generation. Many countries have already taken measures to develop a suitable plan to provide such facilities to their citizen. As the epidemic scale of dementia is large, governments and all segments of the society must come forward to mitigate such disease which has no specific cure in order to facilitate people with a better quality living. So all the worldwide joint effort, governments, approach producers, medicinal services experts, specialists, Alzheimer affiliations, and organizations should approach to settle the issue of dementia (Prince et al., 2015).

Chapter 3 AD in Bangladesh

There is not much information available about AD in Bangladesh. There is no specific epidemiological data set of AD patients of the country. Bangladeshi people are less aware of the bad impact of the Disease. They are not economically solvent about to focus on such resolution to combat AD. On the other hand, Bangladesh has more young population than old age people which will turn to be aged population within 30 years and the necessity of controlling disease may rise to a great extent. In addition to that the health status of our population is not in a good status. They are less concerned about healthy diet intake which may cause more bad impact and raise the propensity of AD. However, smoking habit of Bangladeshi people may also be the cause of the rise of AD in future. It is found that about 44.7% among adult are habituated to smoking and around 43.6% population aged 15 years or above smoke daily. That is why Bangladesh has become one of the largest tobacco markets of the world. But this fact may be the reason for raising the number of AD patient within few decades. In fact the obesity level of Bangladeshi people is very high. People aged more than 30 years or above are overweight. The obesity level among children is lower in number though the children belonging to rich and middle class family seem to be overweight sooner or later. This may also be the reason to cause a hike in the number of AD patient. So we should apply an all out effort to take corrective measure for controlling the bad impact of AD

in Bangladesh. Our government, society, researchers, doctors should prepare themselves to diminish the forthcoming heath problem among the population (Rahman, Tajmim, Ali, & Sharif, 2017)

Chapter 4 Causes of AD

There are a myriad number of factors causing the raise of AD, but among those cerebrovascular irregularities and its antecedents are the prime causes of this disorder. Diabetes mellitus, high blood pressure, smoke, over body weight and dyslipidemia are responsible for such disorder relatively. Moreover, neural disease, large cortical encirclement, single strategically placed encirclement, multiple small encirclement, cerebral internal bleeding, cortical changes resulting to hypo perfusion, white matter changes and vasculopothies, are influential to dementia too. A report regarding these factors is given below:

1.1 Factors causing threat to AD

Table 1: Causes of AD

Influence	Route	Probable mechanism
Cardiac Disease Strategic location ↑ Aβ disposition	Elevated	Parenchymal destruction
Smoking Oxidative stress	Elevated	Cardiovascular effect
High blood pressure	Amplified and minimised	Microvascular disease
Type II diabetes Insulin and Aβ struggle to be cleared	Elevated	Cerebrovascular effect

Influence	Route	Probable mechanism
Obesity	Elevated	Elevated the potential of insulin dependent diabetes
hurtful head wound protein	Elevated	Increase amyloid-β and APP accumulation

4.2 Diseases of veins and arteries

The evidence is clear that disease of veins and arteries of CNS and prototype AD exist simultaneously. Around 7% of new-onset AD occurs after first stroke; rate of prestroke cognitive function is not dependent for doubling the threat for AD at the after stage of stroke though the before stroke cognitive task will neither an evidence for stroke or AD. The process by which stroke may prompt psychological disability incorporating cerebrum parenchyma decimation with decay, hampering strategic placement that brings to amnestic syndrome, for example the combination of vascular & AD type pathology, increasing Aβ disposition and thalamic stroke. However increase in amyloid precursor protein processing is the result of levels of BACE1 which happen because of over expression of p25 and cdk5 related to hypo perfusion which in turn increase Aβ level according to the rodent models of ischemia and hypoxia. In case of MRI, high frequency of hyper intensities is observed in AD patient but the causes of cognitive decline with the contribution of white matter changes are unclear. Hypertension, diabetes and micro vascular disease are dependent for the alteration though any specific processes are known for the detection of the effect of mental changes during AD. Thalamic vascular infection can cause less execution of subjective exercises particularly frontal and mature projection work that renders memory failure and recovery (Mayeux & Stern, 2012).

4.3 Type II Diabetes

The appearance of type II diabetes is related to twofold increased risk of Alzheimer that varies between the ratios 1.5 to 4.0. it is observable that diabetes cause excess deposition of amyloid-beta in CNS and result in high amount of insulin in the blood along with insulin dependent diabetes that deviate amyloid-beta clearance from brain because of the competing manner for the insulin degrading enzyme. Propelled glycation final result receptor that plays a vital effect in the pathogenesis of diabetes is available in cells related with SP and neurofibrillary blends are case of cell surface receptor for amyloid-beta. Surplus fatty tissue might produce adipokines complex for metabolising and cytokines crucial in irritation leading to diabetes. Adiponectin, leptin, resistin, TNF-α and IL-6 may too be formed side by side with insulin oppose and hyperinsulinemia which directly or indirectly can cause AD (Mayeux & Stern, 2012).

4.4 Hypertension

Blood pressure contributes to late life dementia. Elevated BP as well as hypertension during mid years of life span may be the reason for the rise of AD in later part of life. In fact both high and abnormal low blood pressure may be the causes of initiation of AD. When affected by AD, blood pressure begins to decrease, associated blood vessel starts to stiff, weight loss are occurred and automatic regulation of blood flow is disrupted (Mayeux & Stern, 2012).

4.5 Smoking

Initially it was found that smoking may lower the chances of AD disease but later revealed that it might have a neutral or negative impact which eventually might be the cause of growth of the disease. Smoking enhance the risk of dementia by augmenting cholinergic metabolism and by upbringing the cholinergic nicotine receptors in the brain. Raised oxidative pressure, brought about by smoking. these activities and oxidative pressure are related as a probable

AD instrument that produce free radicals and influencing fiery safe framework that may start phagocytosis which cause progressively oxidative demolition (Mayeux & Stern, 2012).

4.6 Body weight

Plenty of cases found that being underweight earlier increased the chance of dementia for example atrophy. Several other studies found that both being underweighted and over weighted can cause dementia. A meta-analysis related to obesity demonstrated a severe impact and the risk of AD. The process by which body weight cause disease is unknown but it is probable that it affect insulin resistance and co-incidence of type II diabetes (Mayeux & Stern, 2012).

4.7 Traumatic Brain Injury

Anyone suffering from brain injury has an elevated risk of initiation of AD, specially who carries the APOE-ε4. A history of traumatic brain injury concludes that men are most likely to be affected by AD compared to women. When human brain injury occurs, both Aβ disposition and intraneuronal tau pathology begin to rise, Moreover CSF Aβ and APP level increase drastically (Mayeux & Stern, 2012).

Chapter 5 Amyloid hypothesis

This speculation expresses that due to change in proteostasis, one of the signs of maturing; APP is separated to make Aβ and when this happens without control, this pathology results. This amyloidogenic proteolysis licenses course of action of fibrils that store extracellularly, slaughter neurons and produce otherworldly SP (McGeer & McGeer, 2013). In any case, unmistakably these SPs usually found among CNS without any subjective pathology. So, it is a matter of concern that in which extent Aβ act contrastingly in patients contrasted with sound individuals. Only a few attaching point of amyloid-beta on various cell yet necessarily on microglia, that known as CNS WBC which may inundate amyloid-beta and destroy them.

In any case, By a time of period this procedure be bypassed, moreover in light of the fact that Aβ generation turns out to be overwhelmingly expanded or due to the "senescence" of the microglia that lose capability, bringing about Amyloid-β beginning toward gradually amass as well as store in plaque. In equivalent, like microglia is unfit to swallow all the Amyloid-β, infectious agents, example acknowledgment binding site (PRRs, for example, the TLRs, CD36, RAGE) sense the closeness of Amyloid-β and actuate solid provocative response prompting free radical and pro-inflammatory cytokine creation (Venegas & Heneka, 2016). This will prompt the well-depicted neuro irritation as well as the damage for neurons. Meantime, Tau protein that is important to upkeep axonal structure, progresses toward becoming more-phosphorylated due to incendiary procedure, as well as structures NFTs, that negatively impact the configuration of neuronal procedures driving primarily to corruption of neurotransmitters as a result neuronal destruction (Holtzman et al., 2016). Along these lines, as indicated by this model, Aβ is at the inside phase of AD at all ailment stages. In any case, without any observable accomplishment of medicines dependent on the amyloid theory, contending speculations earnestly require thought.

Chapter 6 Vascular Theory

The hypothesis related to vessels which carry blood, is under discussion from around nineties. Amyloid-β production could be a consequence of low blood supply (ischemia) in CNS along with increasing age. Amyloid angiopathy of cerebram (CAA) is notable compensating stage because this is considered as storage and spreading segment of amyloid by means of venous supporting system to particularly in the sensory system and thus progression of AD catalyzed. These microorgasomic occasions initiate the introduction of different pathological situation like drainage in cerebrum, hindered blood supply in brain as well as low blood supplying areas where necrosis occurs, subarachnoid discharge, seizures, psychological debilitation, and dementia (Bu, Liu, & Kanekiyo, 2013). A list of risk factors

have been identified through epidemiological examination that influence AD, these risks factors includes DM, fat deposition inside arteris (atherosclerosis), high blood pressure,low blood supply to organs specially in CNS, micro vein and artery related trauma and habit of inhaling tobacco. These factors have effect on vascular processes that whittle passage of blood in cerebrum (de la Torre, 2002). Formation of Amyloid-β and veins or artery focusing theories might merge together with theory of infection. It is believed that AD might have an in between structure which integrate both the theories. At first a single could prevail, however toward the last both may end up unclear. Along these lines, while we can perceive that vascular changes may some way or another contribute, these are a long way from clarifying the majority that is responsible behind developing AD.

Chapter 7 Infection-based Theory

This disease theory has been displayed alike speculative contributing clarification for the first time through Alois Alzheimer as well. The speculation has been disposed, however it is being recalled after for many times (Itzhaki et al., 2017). This rebirth of speculation, that microbes may have an essential job during advancement of AD further was revived for spearheading work of Itzhaki's gathering, he demonstrated plaques include remainders of Herpis Syndrome Virus-1 Deoxyriboneuclic acid (Wozniak, Frost, Preston, & Itzhaki, 2011). This was one of the principal events to interface AD obsessive trademarks to an option that is other than Aβ. The theory recommends that in individuals contaminated by HSV-1 (most of older people), some demonstrate a decrease of the invulnerable framework with age which empowers HSV-1 to relocate from the fringe to the cerebrum, or on the other hand, in upsetting conditions, HSV-1 infects the brain legitimately by means of the smelling nerve. If Herpis.S virus reaches CNS, can encourage a few procedures which add to neural inflammation (like dedicated incitement to TLRs), just for coordinating neuron related cytopathology followed by neuronal destruction (like SP development). Supporting test information suggests Herpis.S

virus-1 in CNS directly influence conversion of amyloid-β from APP sequentially the amass thus excess phosphorylation of TAU (Itzhaki, 2017). additional test information proposing different infections, for example, CMV, may likewise be associated with the pathogenesis of AD (Lövheim et al., 2018). It is not a specific specialist but different microbes might be associated with activating AD pathogenesis (Carter, 2017). A second spearheading group of agents, conjuring the disease theory, has proposed a job that spiral shaped bacteria might have an influence in disease progression of AD (Judit Miklossy, 2012). Specified Oral microbes might have influence during AD, to be specific Treponema, of which there are a few animal varieties in the oral microbiome. Treponema pallidum, the irresistible operator of syphilis, despite the fact that not an oral treponeme, can attack the cerebrum and incite an endless contamination prompting neurosyphilis, which has regular highlights with AD, because of its capacity to avoid the resistant framework. Oral treponemes have likewise been found in the CNS and may likewise have the capacity to productively dodge the immuno system and incite constant contaminations. Bacterial inter communication through gut-brain axis might have contribution in developing AD is believed now a days (Alkasir, Li, Li, Jin, & Zhu, 2017). Lastly it is considered fungi has contribution on this disease processing (Pisa, Alonso, Fernández-Fernández, Rábano, & Carrasco, 2017). Several bacterial presences inside the brain of AD patients are strongly evident though it cannot be said to be an infection based disease.

Chapter 8 Major Therapeutic Pathways for AD

8.1 Active Immunotherapy

Active immunization is still the more feasible approach over other approaches for Alzheimer disease if the vaccine is safe, properly immunogenic for aged people finally should not interfere with the production of auto reactive Th cell in vaccinated body. A variety of peptide or recombinant protein epitop vaccines are produced which are composed of a tiny amount

immunodominant self B cell epitops of β-amyloid 42 and not more than two universal foreign Th epitop. These types of antivaccine showed considerable amount of therapeutic potential as anti β-amyloid antibodies other than activating potential harmful autoreactive Th cells. On the other side this process initiate titers for anti β-amyloid antibodies and these titers also interfare accumulation of β-amyloid (Davtyan et al., 2014).

8.2 Passive Immunotherapy

Due to occurrence of vasogenic edema and in few cases brain micro hemorrhages cognitive efficacy of bapineuzomab appears uncertain preliminary. Solanuzomab is another monoclonal antibody which has given positive result in neutralizing β-amyloid oligomers and is believed to be more neurotoxic β-amyloid species. A good safety profile was found in phase-2 trial of solanezumab. Analysis on cerebrospinal and plasma biomarkers has given satisfying data about pharmacodynamic activity as well. Though primary ambiguous cognitive results illustrated from bapinuzomab and principal cognitive results illustrated from semagacestat(a potent γ-secretase inhibitor) shows possibility that controlling β-amyloid might not be clinically efficious in AD. There are four large phase-3 ongoing on bapinuzomab and two on solanezomab thus we may know whether it is feasible to control this disease by passive β-amyloid immunization (Panza et al., 2011).

Chapter 9 Amyloid-beta:

Pathogenesis of some neurodegenerative diseases are dependent on protein aggregation followed by protein deposition. All these types of diseases are classified as proteinopathies. Proteinopathis are further classified depending on the specific protein responsible for a specific disease. AD is a continuous neuropathic disease. Neurotic plaques and NFT’s mostly represent AD. Aβ is one of the key factors in plaque formation. A wide range of experiment



Figure 1: Amyloid beta structure. Adopted from, (Surin, Grigorashvili, Suvorina, Selivanova, & Galzitskaya, 2016).

have been done and results are obtained upon β-amyloid (Surin, Grigorashvili, Suvorina, Selivanova, & Galzitskaya, 2016). Amyloid beta is present in the organisms and plays physiological function when it is in normal state. Amyloid-β derives from a precursor of the β-amyloid protein, or APP, this precursor protein, an amyloid glycoprotein transmembrane with N-terminal portions outside cells and the C-terminal portion inside. Amyloid precursor protein goes intramembrane controlled proteolysis. There are two specific pathways for this proteolysis process.

- Non-Amyloid process
- Amyloid process

9.1 Non- Amyloid Process

In non-amyloid process α-secretase cleaves N-terminal portion of APPsα which contains a portion of β-amyloid peptide sequence on the other side the left over part C83 is processed by

γ-secretase. This process ends up by releasing two different parts one is Peptide p3 and the other is Amyloid intracellular Domain (AICD) of APP.



Figure 2: Amyloid precursor protein proteolysis process. Here, AICD- Amyloid intracellur domain, PS- Presenilin, APP- Amyloid precursor protei, Asopted from, (Surin et al., 2016)

9.2 Amyloid Process

When this cleaving process is amyloidogenic β-secretase compete with α-secretase and cleaves the APP peptide chain 16 amino acid earlier than α-secretase from the N-terminal giving APPsβ also leaving Aβpeptide intact. The left fragment C99 is further undergoes enzymatic lysis by γ40 and γ-42 secretase that forms Amyloid-β peptide (1-40) and Amyloid-β peptide (1-42) and AICD. Amyloid formation mechanism of Aβ is studied extensively, nucleation dependent polymerization is the most accepted theory which Suggests that formation of these fibrils requires a structured nucleus and its formation is guided by mutual

addition of Aβ peptide molecules after the concentration of monomer reaches a critical state. Though the nucleation state is a limiting stage it is further strengthen by a lag-period. A simplified system for the fibrils formation follows three stages:

- Change in the monomer state
- Oligomer structure formations
- Mature fibrils formation.

Naturally Aβ peptides are amphiphilic soluble monomers. The mass of 42 amino acid containing monomer is 4513.1 Da. The sequence of a monomer having 42 amino acid is (DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA) whereas Aβ(1-40) is differentiated by the absence of Ile and Ala in C- terminal as a result its mol. Weight turns 4329.2 Da. An amyloid preparation was studied by Electron microscopy fibrils were found in solution. It was also observed in different point of temperature at different stage of incubation. Even in the zero hour of incubation fibrils were identified in the solution, fibrils were not branched and they had an average diameter of 8nm. Fibrils kept increasing following the incubation time. The peptide of C-terminal region accumulate usually, in all C-terminal region 28-40 no amino acid containing part is resistant to protease action and in 16-22 amino acid containing part is also resistant to protease action. This states that 16-22 and 28-40 amino acid region responsible for spin formation of amyloid fibril (Surin et al., 2016).

Chapter 10 Senile plaque

Numerous biological products might be found inside the biofilm relying upon the kind of pathogen and the encompassing substances. Along these lines, microorganisms in biofilms show raised resistance to stress and anti-infection agents, just as to insusceptible intervened assaults giving to this entire structure a perfect specialty to guarantee the diligence of the microorganism in nature and for the most part, in relationship with the host. While thinking

about this disease speculation as well as opposing activity of Aβ for microbes, The other believe is SPs present in CNS are responsible for certainty guaranteeing the continued



existence of different infectious agents (polymicrobes) (Judith Miklossy, 2016).

Figure 3: Formation of senile plaque. Here, AICD- Amyloid intracellur domain, APP- Amyloid precursor protein, Adopted from,(Judith Miklossy, 2016)

HSV-1 DNA is observed in the plaques and thus it can be considered that senile plaques(biofilms) contain different neuclic acid (Natrajan et al., 2008). It is crucial to understand structural activity of SP. Within SPs, spiral strands, actually amyloids of microbes, which sum as well as obtain Amylois-β-like compliances as well as go for cross-seeding atoms for spreading (Taylor & Matthews, 2015). Undoubtedly, SP filaments found in a profuse number among microorgasomal parts as well as considered as the most important basic for practical outer celluler framework parts for environmental and infectious bio protecting agents (Müller, Deller, & Korte, 2017). In this manner, It would be hypothetically considered to add Aβ in the brain, which will at last produce SPs, to these microbial elements which establish the basic structure of the bio protecting layer (Torrent, Pulido, Nogués, & Boix, 2012). One of four noteworthy proteins found in the presenilin complex, PSEN1 is encoded for by the PSEN1 gene as depicted by the focal authoritative opinion. This PSEN1 protein is then used in managing the dimensions of APP delivered within cerebrum. An overproduction of this APP prompts the arrangement of the neurofibrillary tangles and amyloid plaques present in those with AD, seen underneath: The delivered senile plaques, causing neuronal cell demise and rot, regularly prompt diminished brain capacity and effectiveness. Together, this data shows the multifaceted nature of AD, the means by which PSEN1, a protein engaged with the guideline of both APP and gamma-secretase, is the beginning of the disease phenotype chain response (“Presenilin I Protein - AD:the influence of presenilin I,” n.d.).

Chapter 11 NFT’s (Neurofibrillary Tangles)



Figure 4: Formation of NFT's Adopted from, (HUTTON, 2010)

Tauopathy is an obsessive accumulation of tau protein, a type of neurodegenerative infection known to be the neurofibrillary (NFT) tangle in the human CNS. It has been found within a large group of age dependent diseases like AD, PiD, Progressive supranuclear palsy (PSP). For neurological disorders, The rate of neuronal loss is far higher than NFTs, suggesting that NFT formation and neuron death may be a common mechanism (Ingelsson et al., 2004). This speculation is emphatically upheld by the revelation of a tau quality change in frontotemporal dementia with parkinsonism connected to chromosome 17 (FTDP-17) (Goedert & Spillantini, 2000)(HUTTON, 2010), a twisting illness related with NFT arrangement and neuronal misfortune. The explanation of transformed tau in FTDP-17 indisputably shown, that tau brokenness or variation from the norm alone can instigate neurodegeneration, portrayed by NFTs and neuronal demise and prompting clinical dementia. A FTDP-17 mouse model that

demonstrates age-related NFTs, neuronal end, and lead deficiencies may uncover understanding into the issue of how tau activates neuronal brokenness. These mice over express P301L crack tau under the rule of an anti-infection medicine inducible promoter. In spite of the fact that restraining freak tau over articulation in these mice squares neuronal demise and improves memory, NFTs keep on shaping (Santacruz et al., 2005), demonstrating that NFTs may not be in charge of neuronal passing. Ongoing perceptions that NFT-bearing neurons contained enacted caspase however did not experience intense apoptosis (Spires-Jones et al., 2008) prescribe that NFTs are not themselves deadly, anyway that fairly the instrument of NFT advancement is shared by the strategies covered up neuronal downfall and neuronal brokenness. The association between neuronal mishap and memory brokenness in the P301L crack tau mouse show remains ill defined. Nonetheless, an examination of NFT development may uncover the way to understanding tau-actuated neuronal dysfunction (Takashima, 2010).

Chapter 12 Tau Pathology

Tau is a member of the MAP family of microtubule proteins. This is also necessary for the assemblage of Microtubular cytoskeleton and its stabilization. On the other side it is in of the essential components of Paired helical filament (PHF) which further get associated with



Figure 5: Nurofibrillary tangles. Adopted from, (Nizynski, Dzwolak, & Nieznanski, 2017).

nerufibrillary tangles (NFTs) and this NFTs are a dominating component of AD. AD is undoubtedly related with neuronal death caused by Tau aggregation or its oligomerization and it is also responsible for showing the toxic effect of Aβ. Hence, in treatment with Aβ amyloid aggregates, Neurodegeneration is not susceptible to tau-depleted hippocampal neuron. It is considered that Aβ and Tau aggregation have some interrelation some studies states that Aβ aggregates can accelerate tau hyperphosphorylation thus moving towards degeneration of hippocampal neurons. Mutual aggregation process of amyloid beta and tau might be the trigger for AD. According to different recognized processes tau amyloidogenesis emerges through a nucleated polymerization process that is common in different amyloidogenic protein. This Tau fibriliztion process is composed of three different periods:

- A lag period
- An elongation period
- Plateau formation phase

The precursor protein molecules are then fed mature amyloid fibrils during the seed season. Rapid start of amyloid growth and delay removal are observed. It is recognized that a short list of amino acids are crucial for the development of primary stage of Tau aggregation. PHF6 and the a.a sequence is (VQIVYK), PHF6* and the a.a sequence is (VQIINK). These hexapeptide motifs supposed to act as nucleating segment of Tau assembly. PHF6 and PHF6* are attached to the microtubuler binding domain. These amino acid sequences are supposed to increase the tendency of nucleation by increasing the tendency of forming conformations rich in β-sheets. During elongation phase some Tau proteins are gradually converted into amyloid fibrils which are soluble in nature. It is considered that Tau fibrils growth follows zipper like mechanism and finally These processes stop when major protein monomers are converted into amyloid aggregates at the plateau phase (Nizynski, Dzwolak, & Nieznanski, 2017).

12.1 Polyanionic action during Amyloid growth

A bounty of essential amino acids is found in initial formation of Tau and is the top reason of its fundamentally disordered behavior. This character makes tau more comfortable for aggregation by adding dynamicity and also helps to protect aggregation by inducing electrostatic repulsive force. Therefore the excess affirmative charge on growing tau molecules needs to be diminished by phosphorylation or through interactions with anionic species. Physiologically relevant poly- or oligo-anions glycosaminoglycan typically heparin or heparan are experimented frequently to disclose the interrelationship with tau aggregation but smaller anaions like arachidonic acid, docosahexaenoic acid or taurine might also be present in in-vivo aggregation of tau. Among all the polyanionic initiator of Tau aggregation, heparin is mostly thought to be involved in the process. Heparin got longer chain which is considered to be more effective in Tau aggregation. Heparin accelerates tau aggregation process in very early stage by forming aggregation prior dimer. Main regions of Tau are identified which are accountable to bind with the glycos-amino-glycan that contain extremely

charged MTBRs side sequence (Sibille et al., 2006). Primary attachment with heparin favors formation of β-Strands and α-helices among different positions of Tau which are available in 21 disordered form even in the absence of heparin. It is evident that heparin remain in the dense core of amyloid fibrils (Sibille et al., 2006)



Figure 6: Tau aggregation prone dimer of heparin, Adopted from, (Sibille et al., 2006).

12.2 Post Transitional Modification of Tau and Its influence in Amyloidogenesis

A variety of post-translational modifications controls physiological functions of Tau. Partially PTM regulates affinity of Tau to the microtubules (E.-M. Mandelkow & Mandelkow, 2012). Eventually irregular modification could lead to aggregation (Davtyan et al., 2014).

12.3 Phosphorylation of Tau

Phosphorylation and dephosphorylatin has impact on the binding affinity of Tau to MTs (Lindwall & Cole, 1984). Accumulation of hyperphosphorylated Tau is observed in AD and tauopathies as NFTs (Alonso, Grundke-Iqbal, & Iqbal, 1996). An abnormal rate of

phosphorylation balance positive charge on Tau molecule and lead tau to aggregation process (Del C. Alonso et al., 2001). Most of the phosphorylation sites are originate in the proline affluent and c-teminal region of tau, there are four (S258, S262, S289, S356) sites as well in the duplicate area (Hanger, Anderton, & Noble, 2009). S262 site is located in MT binding domain which is phosphorylated in the early stage of AD (Ando et al., 2016). On the other side phosphorylation is observed in normal fatal brain as well without presence of Tau pathology (Kenessey & Yen, 1993). There are some animals whose brain hyperphosphorylate Tau as neuroprotective mechanism during hibernation (Härtig et al., 2007).

12.4 Proteolytic Cleavage of Tau

Tau amyloidogenesis and introduction of neurotoxic spices can be facilitated by proteolytic cleavage of Tau. The protein is susceptible for different caspases (a group of cysteine proteases that demonstration in show in a course activated by apoptosis flagging.) and D421 residue can be cleaved by caspases within neuron when treated with Aβ (1-42) aggregates. Assembly of Tau1-421 is more frequent when arachidonic acid induce fibrilization than the full length molecule (Gamblin et al., 2003). Caspas-3 and 6 are responsible for proteolytic breakdown of Tau in AD. The D25 and D421 residues of Tau are cleaved by caspas-3 whereas D13, D402 and D421 are trimmed by caspas-6 (Gamblin et al., 2003). It is also found that aggregates of Aβ1-40 activate calpain-1(μ-calpin) that in turns stimulates production of 17-kDa N-portion section of Tau (Tau 45-230, 2N4R) that encourage cell death in neuron (Gamblin et al., 2003). 26-230 residues are another neurotoxic fragment that is involved in the process of caspas, calpains can also be involved in this mechanism (Corsetti et al., 2008). 26-28 kDa N-terminal proteolytic fragments of Tau have been found in CSF AD affected brain (Johnson et al., 2002). A 12 kDa Tau section having approximately hundred residues have been found in the centre of PHFs of AD which are lightly resistant to protease (Novak, Kabat, & Wischik, 1993). Proteolytic rearrangement of flanking sequences around

MBD gives aggregation prone structure that catalyze the progression of Tau pathology in human CNS (Nizynski et al., 2017).

12.5 Acetylating modification of Tau

Acetylation of Tau by lysine leads the creation of NFTs and it also protects degradation of hyperphosphorylated Tau, it increase Tau aggregation in vitro as well (Cohen et al., 2011; Min et al., 2010). Acelyteted form of Tau has been found in human brain affected with AD (Cohen et al., 2011; Min et al., 2015, 2010; Tracy et al., 2016).

12.6 Structural Memory in Taupathy

It has been revealed by isolating aggregation of Tau from human brain that it can convert Tau monomers to the prerequisite of Taupathies (Clavaguera et al., 2013; Kaufman et al., 2016). It is remarkable that these sorts of taupathies are possible by getting trans-organism obtained from conformational amyloid seeds derived from diseased brain (Petkova et al., 2005; Shorter & Lindquist, 2005; Surmacz-Chwedoruk, Nieznańska, Wójcik, & Dzwolak, 2012).

12.7 Cross seeding

Cross seeding process might be concerned in neurodegenerative disease because additional deposition of amyloid aggregates is observed in these diseases. More specifically both Aβ and Tau are aggregates are found in neurodegenerative diseases like AD. It is also found that Aβ aggregates catalyze Tau accumulation and makes environment for Tau fibrilization where Tau linked with Aβ peptide ranging from central to C-terminal region (Ferrari, Hoerndli, Baechi, Nitsch, & Götz, 2003; Guo, Arai, Miklossy, & McGeer, 2006; Vasconcelos et al.,



2016). R2 repeat of Tau is interacted with Aβ 17-42 oligomers (Guo et al., 2006; Miller, Ma, & Nussinov, 2011).

Figure 7: Cross seeding of tau, Adopted from, (Surmacz-Chwedoruk et al., 2012)

Chapter 13 Tau based Therapeutics for AD

Presence of increased amount of phosphorylated Tau in cerebrospinal fluid might be the most dependable cause of neurodegenerative disease (Clark et al., 2003). Oligomeric Tau ranging from dimmers to octamers are formed by binding hyperphosphorylated Tau to each other (Sahara et al., 2007). Oligomeric Tau having around 40 molecules creates a β-like structure that forms granuler shape sequentially. This granules are detergent insoluble and supposed to be the cause of neuronal loss (Kimura et al., 2010; Maeda & Takashima, 2007; Takashima, 2010). NFTs therapy has possible application rather than development of drug because drugs that are used against Aβ have gained more potentiality than these. Specific pathological neurotoxic form of Tau needed to be recognized for better Tau based therapies (Medina, 2011; Tariot & Aisen, 2009a). On the other side Aβ oligomers has an adverse affect on synaptic structure and its plasticity (Haass & Selkoe, 2007). Though the finalization is thought to be achieved by NFTs but there is another process which is initiated by some intermediates (hyper-phosphorylated, soluble tau species) that cause neuronal dysfunction (Haass & Selkoe, 2007; Medina, 2011). NFTs are thought to be more secured because tangle carrying neurons survive more than others (Andorfer, 2005; De Calignon, Spires-Jones, Pitstick, Carlson, & Hyman, 2009). It is thought to be possible to stabilize, reduce or stop aggregation by developing tau targeting therapies (Grill & Cummings, 2010). Different Therapeutic processes are in trial to solve this problem (Medina, 2011) :

- Prevention of Tau aggregation process
- Decreasing Phosphorylation
- Boosting MT Stabilization
- Boosting Tau clearance (Medina, 2011)

Different types of chemical agents are within discussion through cellular based mechanism or lab based experiments which are capable of preventing Tau aggregation. Like polyphenols (Grill & Cummings, 2016), phenothiazines (Bulic, Pickhardt, Mandelkow, & Mandelkow, 2010), benzothiazoles (Necula, Chirita, & Kuret, 2005)(Pickhardt et al., 2007), N-phenylamines (Bulic et al., 2007). methylene blue (chloride methylthioninium; Rember™, TauRx Therapeutics, Singapore, Republic of Singapore), drug that has been used to treat malaria which is non-neuroleptic phenothiazine in nature (Akoachere et al., 2007), is in the clinical trial and is about to finish Phase-2 trial among AD patients ("No Secular Trend and High Variability for Adas-Cog Change Among Placebo," n.d.).This drug is capable of dissolving PHFs which has been separated out of AD affected brains and prevention of tau clustering process in cellular experimentation is also observed, further it was found effective in experimenting mice model, sense related and other responsive problems have also been reversed along with reduction of tau-levels in brain ("Piggybac Transgenic Mouse Services | Cyagen Biosciences APAC," n.d.). Methylene blue is also capable of inhibiting a-synuclein, TDP-43 and Amyloid-β aggregation (Iwatsubo et al., 2006)("Neuroimmunology Drug Development - Neuroimmunology Drug Development Summit (NIDD)," n.d.). It increase fibrilar Aβ (not monomeric Aβ) thus decrease Aβ-oligomers in-vitro testing (E. Mandelkow et al., 2013). This compound is still under research along with another one named leucomethylthioninium for more bioavailability and less toxicity during administration of higher dosages (E. Mandelkow et al., 2013). Promotion of microtubule network breakage and lowering tau's attraction for MT causes toxic effects on neuron during AD progression by hyperphosphorylation, irregular folding or inducing tau aggregates (Medina, 2011). Different pathways and unique sites on protein have been found for the phosphorylation of tau (Schneider & Mandelkow, 2008). A variety of tau kinases are present which include, synthase kinase for glycogen 3b (GSK-3b), kinase-5 on which cyclin depend, protein

controlling kinase that are related to microtubule and others. These are under consideration for being dependable kinase sites to induce medication for Tau (Schneider & Mandelkow, 2008). NP031112 (NP-12, tideglusib), the medicine that falls under thiadiazolidinone group currently named as noscria (Madrid, Spain) in clinical trial upon animals having AD shown improvement of cognitive performance, reduction of amyloid accumulation, lowering excess phosphorylation, tau aggregating ,neural inflammation importantly lowering neuronal failure (Vescovo, 2010). Detachment of tau from MT causes decrease of its regular MT stabilizing activity and thus it might lead to axonal relaying destruction and as a consequence to synaptic dysfunction. Some Mt stabilizing chemicals are proposed as anti AD drugs among other anti AD agents (Panza et al., 2012). Different anti mitotic agents like paclitaxel or epothilone are being administered into DNA modified animal models targeting MT stabilizing activity (Yu et al., 2014). NAPVSIPQ (NAP, davunetide), is a peptide having eight amino acids (where NAP shows 3 initial amino acids of that peptide)originated from neuron shielding protein which are activity dependent (Golde, Petrucelli, & Lewis, 2010), has shown potential to lower tau phosphorylation as well as Aβ levels in animal model (Golde et al., 2010). Davunetide is an nasal route preparation (AL-108, Allon Theraputics, Vancouver, Canada), which is now in under observation within stage-2 clinical trial for mild cognitive impairment (MCI)(Golde et al., 2010), and progressive supranuclear palsy (Boxer et al., 2014)(Höglinger et al., 2017), Intranasal administration of NAP got the access after BBB (Höglinger et al., 2017). Lastly,current works for The development of harmless and effective immunotherapy against amyloid-β by using Aβ peptide in case of active immunization as an immunogen on the other side antibodies against Amyloid-β for inactive vaccination could have been followed targetting the growth of tau-dependent immuno treatment (Tariot & Aisen, 2009b).

Chapter 14 Anti Amyloid-β Therapeutics for AD

Potential harmful agents can be cleared through immunotherapies, for this reason approach dependent on vaccination has become a lucrative pathway for the treatment for AD. Finally the process of clearing Aβ from AD affected brain by Aβ antigens in case of active vaccination and by Aβ antibodies in case of passive vaccination gives the most novel system for therapy against AD (Wisniewski & Konietzko, 2008). The pharmacological system behind vaccination against Aβ is dependent on the natural response of the body which is created for due to giving anti Amyloid-β antigens or anti Amyloid-β antibodies (Wisniewski & Konietzko, 2008). Different types of experiments have been suggested a variety of immunological methods on focusing SP reduction, active immunotherapy along with Aβ peptide of first (Wisniewski & Konietzko, 2008) and second generation (Frey et al., 2011) and depending on short immunogens of Aβ (Frey et al., 2011)(Sigurdsson, Scholtzova, Mehta, Frangione, & Wisniewski, 2001), phage-peptides are administered through intranasal route and monoclonal antibodies are administered through intraperitoneally by injection for systemic passive immunization (Bard et al., 2000). Amyloid-β removal mechanism out of brain is still undiscovered and is believed that direct clearance of Aβ deposits is included here(Bard et al., 2000), restriction of Aβ aggregation (Bard et al., 2000) and withdrawal of Aβ from periphery are also followed('sink phenomenon') (Sigurdsson et al., 2004). Preaggregated synthetic Aβ1-42 and an immuno catalyst QS-21was added to the firstly initiated active vaccine named AN1792.It was reported by post mortem biopsy report and testing on transgenic mouse model that pharmacologically AN1792 was capable of reducing Amyloid-β occurrence consecutively in AD affected brains. Meningencephalitis was caused among 6% of the models who were given AN1792 during phase-2 trial having mild to moderate AD. This vaccine was halted due to negative clinical significance and doubted efficacy. After this halt a varieties of active and passive immune agents were launched

targeting to diminish the adverse effects that were found in AN1792, consequently different other Anti Aβ agents (both active and passive) were prepared targeting to diminish or abandon unwanted effects found in case of An1792 (Panza et al., 2012). New tau-dependent therapeutic system have been experimented since last couple of years because of thwarting clinical outcomes at late stage trials of anti Aβ immune agents and Aβ based pharmacological processes (Medina, 2011). Recently, A variety of immune based therapeutic systems are under supervision on near clinical subjects targeting tau removal depending on tau based antibodies and primary statistics of these experiments suggested that this system could play vital role in tau deposit clearance in AD affected brains. Though unphosphorylated full-chain human tau protein besed immunotherapies on natural type mice conducted the emergence of encephalomyelitis along with changes in nural system and normal behavior on the other side damage of axons and caused inflammation (Boimel et al., 2006). It is reported that the tau phosphopeptide vaccination process have ability to reduce NFT load on brain along with spinal cord devoid of inducing nurotoxicity (Boimel et al., 2010). Stoppage of behavioral destruction and avoidance of development process of NFTs have been observed while targeting misfolded, AD specific and truncated forms of tau (Boimel et al., 2010). Hence it resembled that antibody respons could be brought out by aiming on abnormally phosphorylated tau epitops or related conformers thus could lead to tau clearance. Newly a system based on reactive immune treatment is introduced in laboratorial segment, depending on attaching guided MAB having elevated attaching capacity to 300-QPGGGSVQIVYKP-312 portion in tubulin binding portion of tau which is believed to be able to delete etiological manner of MT production that is induced by uncontrolled structure of tau (Panza et al., 2012).

Chapter 15 Active Immunization for AD

A usual system for generating planned antibody response in patients by administering a drug or selected chemical agents is active immune process. After getting a notable result mentioned previously while preclinical experiment by pre accumulated Amyloid-β1-42 along with protected Freund's catalyst to improve response, a primary experiment was done in United Kingdom on eighty patients having less to medium AD for knowing toxicity as well as antigenicity when administering several dose of AN1792 (Donoghue et al., 2011). At the secondary phase of this phase 1 experiment an emulsifier named polysorbate 80 was included in the vaccine (Pride et al., 2008). Consecutively during second phase of clinical study on 372 AD affected person, 300 models have been given AN1972 and poly-sorbate80. Due to the problem of meningoencehalitis found in 18 subjects who were vaccinated in this experiment this experiment was abundant (Michel et al., 2012). An excess level of Th1-mediated response was found in the autopsy because of Cytotoxic T-cell reactions around a few of the cerebral vessels (Ferrer, Rovira, Guerra, Rey, & Costa-Jussá, 2006), Though the specific reason of toxicity among those patients is still in the dark. Il-2 and IFN-g indicative class 2 CD4+ and Th-1 type response were produced in majority of the patients, secondary blood mononuclear cells which showed an anti Aβ antibody response while stimulating with Aβ invitro (Pride et al., 2008). Matter of interest was Aβ immunotherapy lead to accumulation of T-cell in SP's of the brain collaterally it initiated activation of microglia and a proficient clearance of Aβ (Fisher, Nemirovsky, Baron, & Monsonego, 2010). Vaccination has the ability to boost amyloid clearing mechanism as vaccination cleared parenchymal plaques observed in post mortem histopathological report of some examined patients (Ferrer et al., 2006). Roughly 25% of the AN1792 administered patients developed a defensive Amyloid-β antibody reaction. It is found persons who developed antibody reaction had a gradual noticeable development among different cognitive tests in contrast to starting standard on the

other hand a minimum decrease of daily life activities comparing to the patients who were not given antibodies (Holmes et al., 2008)(Hock et al., 2003) . During a sub analysis of Zurich group with AN1792 phase 2a trial (Hock et al., 2003). It was noticed that antibody responsing persons had better memory functions than no responders and the placebo treated patients (Holmes et al., 2008). This outcome could play a little mental effect in those patients who are placebo treated (Michel et al., 2012)(Holmes et al., 2008). Pre administration of AN1792 to the susceptive patients before they generate AD oriented pathology clinically and this theory is strengthen by the observance of tau oriented pathology on parts of brain cleared of Aβ. Early immunization at the primary stage of this disease might be able to increase the Aβ decreasing effects (Götz, Chen, Van Dorpe, & Nitsch, 2001). In fact production of Aβ deposits as well as hyperphosphorylated tau aggregates were reported to be stopped by early vaccination in transgenic mouse models having AD (Oddo, Billings, Kesslak, Cribbs, & Laferla, 2015). A proper modification of Aβ-peptide that has antigen might be able to give a lymphatic response and might reduce the ability which is needed for Th-1 mediated response. A perfect anti amyloid vaccine is expected to produce a bias stimulation to give Th2 immuno response to bring out a strong anti Aβ antibody (Lemere & Masliah, 2010b). A variety of second generation active anti Aβ vaccines are on the play like soluble Aβ derived immunogens (K., H., & A.M., 2012), phage display of Aβ3–6 (Frenkel, Dewachter, Van Leuven, & Solomon, 2003), N-terminal Aβ fragments (Agadjanyan et al., 2005), HSV amplicons coding for Aβ (Frazer et al., 2008), DNA Aβ vaccines which are not virus derived (Okura et al., 2006), Aβ N-terminal fragments programmed with DNA vaccines (Movsesyan et al., 2008) as well as Aβ ‘previously following particles (Bach et al., 2009). In addition a variety of new particles as well as different dosing pathways (oral, intranasal and transcutaneous) are experimenting to advance the protection, effectiveness and simplicity of using anti-Aβ vaccination (Lemere & Masliah, 2010a). Presently mucosal route is

specifically point of choice because of its eliciting capacity of lymphatic response. This situation arises because of the availability of mucosa in nasal space and GI tract. The administration of vaccine through lymphatic route provoke antibody secretion of IgA type, yet some time antigen is given and catalyst as well (cholera toxin part B or heat-sensative E. coli enterotoxin) strong immunoglobuline-G response expected to be resulted (LEMERE et al., 2010)(Zhang et al., 2003). A matter of interest was a proteosomebased adjuvant given through nasal route in juvenile mice it stopped Aβ accumulation and affected Aβ deposition and among mice who had heavy amyloid and aged as well got functional changes in memory, side by side the conciliation of secondary creation of microglia with no evident possibility of toxic effects (Frenkel et al., 2008). Undoubtedly administration of Aβ through nasal route noticeably lowers amyloid load other than affecting cell to produce immunological reactions (H. L. Weiner et al., 2000).

15.1 CAD106

CAD106 is a present active vaccination process which gives strong antibody respons while not initiating T-cell. A wild type mouse was given CAD106 for three times for observing the dose amount needed for Aβ antibody reaction and the founded dose amount was in between 75 to 225µg. The 25µg dose amount was found near but not under the area of dose stability and this amount was further chosen for experimental purposes on mice model. The activation levels of T-cells which are specific to Aβ were observed when there was administration of following three immune agents in mice model:

- Aβ1-42
- Freund's adjuvant
- CAD106

A phase of ten days from the last administration of the immunogens spleen cells were collected for the stimulation, when all the administered models have developed antibody titers then stimulated with a varying Aβ epitops, interferon-γ and T-cell mediated dots were measured. Except peptide dependent stimulated models other CAD106 models gave conditional values. On the other side experimenting subjects, which were injected Aβ1-42 showed increment three to four times in number of Aβ reactive T-cells when stimulated with Aβ1-40 or Aβ6-20 here each of them contained T-cell epitops. On the other side it was confirmed that there was lacings of T-cell epitops for revers peptide (Aβ40-1) and antigen of CAD106 (Aβ1-6-GGC) as there was no stimulation. Qβ-reactive T-cells are needed for supporting T-cell and it was reported in favor when immunized with CAD106. Antibody feedbacks were noted for each experimenting subjects for measuring amyloid evidence estimation. Two groups were divided the standard group got PBS and experimenting group was administered with CAD106. Aβ antibody titers were almost negligible in PBS given group collaterally the group given CAD106 has developed Aβ specific IgG more than ten times than the identifying level. The average level of titers in immunogen given groups were in between 10-110μg/ml measured from the third input to onward and being an active immunization process the level fluctuated in all over the study. There were no evident difference found for antibody feedback among APP23 and APP 24 transgenic mice models and wild type mice. In cerebro spinal fluid the amount of Aβ antibodies were not detectable or higher than the limit of detection in some cases. A tiny amount of antibodies were found in cerebro spinal fluid from the mice models as there was a little amount of Aβ antibodies got mixed with CSF. A noticeable amount of IgM to IgG movement was observed while treating with CAD106. From there on, Aβ explicit antibodies of all IgG subclasses were found with some variety in subclass proportion noted between different living experimental subjects. Except a few cases subclass pattern for every animal were almost constant with time. The

number of amino acids from 3-6,(E)FRH of Aβ were recognized by the antibodies having a negligible epitop (Frey et al., 2011).

15.2 AC Immune SA (ACI-24)

This Vaccine is dependent upon the conformation, the epitop is constructed of a sequence of amyloid-β (1-15) that acquire aggregated structure of β-sheet when get attached to the liposomes. Actually this vaccine is modified focusing aggregation and fibrilization of amyloid-β. Reduction of insoluble amyloid-β 40 and 42 during preclinical study on mouse is observed. Cognitive work seen improved and a increased level of amyloid-β titers was also observed 33.In 2016 AC immune started a dose guidance trial. It is the very first vaccine that is recognized for the treatment of AD in Down's syndrome. This experiment is believed to be completed in middle of 2020. There by we may know the safety, efficacy of this vaccine (Muhs et al., 2007)

15.3 Araclon Biotech vaccine (ABvac40)

This (Araclon Biotech) vaccine is developed by targeting C- portion of amyloid-β 40. Several repeats of tiny C- terminal residues are comprised to make this vaccine along with aluminum hydroxide. Different doses of this vaccine have been tested to make it compatible within human body. There were no symptoms of vasogenic edema, microhemorrhages or amyloid related imaging abnormalities. The patients who received all the structured doses of this vaccine have shown specific response against amyloid-β 40. Trial of this vaccine is estimated to be finished in 2021 (Muhs et al., 2007).

15.4 United Neuroscience (UB 311)

This vaccine is to facilitate B-cell and a modified Th2 response. This vaccine is comprised of double amyloid-β 1-14 chain together where they are also linked with helper T- cell and this

is administered through Th2 alike delivering process. A positive response has been seen when studying on animal models. When giving 300μg/dose through IM, the vaccine showed tolerance and produced increased level of anti- amyloid β activity. As this vaccine is still not have a controlling group it is kept for further assessment. This vaccine is beneficial for the treatment of mild AD patients (Herline, Drummond, & Wisniewski, 2018).

15.5 Tau Based system

Functional development of neurons and removal of tau pathological agents were observed in active immunotherapy system through creating anti tau antibodies in tau based active immunization process (Solfrizzi, Logroscino, Santamato, Greco, & Pilotto, n.d.). The beginning of active immune therapy experimented on a protein named (P301L) and it was a type of mutant protein of human (JNPLI3 P301L) and A transgenic mouse tau phosphopeptide with a chain of thirty amino acids with aluminum active ingredient of amino acids from 379-408, was published by Asuni and colleagues in 2007, There were phosphor-Ser residues at positions 396 and 404 both of these are related with NFTs (Solfrizzi et al., n.d.). DNA recombinant JNPL3 P301L tau-communicating rats given a tau focusing result where totaled Tau protein and neurofibrillary tangles promptly collect in the some specific areas like voluntary implus generating section, overall in the brain and in the spine motor during their 5 months, where remarkable neuronal transmission defects(Hutton et al., 2000). Immunohistochemical and biochemical investigations exhibited a particular counter acting agent reaction which decreased tau accumulation those had a phosphet group through different parts of the antibody (Hutton et al., 2000). Characteristical analysis utilizing the rotarod and cross bar indicated improved execution on engine assignments after vaccination as contrasted and controls treated with only adjuvant (Hutton et al., 2000). When youthful creatures were immunized by starting 60 it started lowering disease causing pathways during 150-240 days and within few cases 96% clearance was observed .Antibodies against this

immunoge have the capability to overcome blood brain barrier and could get attached with tau having phosphate group got exposed (Hutton et al., 2000). In the mice, the clearence of tau was related with charecterestical enhancements, while the impact in the prevention of subjective decrease couldn't be resolved since motorimpairments meddle with regular trial of information accumulation and knowledge gaining process, Rosenmann and associates experimented modified tau of human species which were free of phosphorylation in place of immune responsive particle and its emulsification was done with Freund catalyst or pertussis antigen among rats of natural types and those showed inflammation of brain as well as caused harmful antibody response (Hutton et al., 2000). The mice immunized with dissolvable tau produced nurofibrillary tangles like models, neuronal deffect, hypertrophy of glial cells, single neuclic invasion (Hutton et al., 2000), strengthen theory about adverse effects on neurons by tau directed vaccination process. Mentioned experiment shows the capable harm character of using tau that can be dissolved in place of protecting substance for treatment. Peculiarly, vaccination with a mix of three particular tau phospho-peptides (Tau195– 213 [p202/205], Tau207– 220 [p212/214] and Tau224– 238 [p231]) containing the alzheimer's or tau disease induction related upper surface, in DNA modified rats overexpressing a twofold freak human tau protein (K257T/P301S) (Rosenmann et al., 2008), provoked a 40% decreasing in a bad position in cerebrum and spinal line with no proof of causing encephalitis encephalitogenicity, clinical neurological insufficiencies, adversarial ramifications for cns provocative cells and axonal mischief after a long development (Boimel et al., 2006). Recently, two different investigations detailed beneficial outcomes after vaccination with tau phospho-peptides (Boutajangout, Quartermain, & Sigurdsson, 2010). the main report utilized a similar thirty-NH2 corrosive tau peptide which are phosphate attachedfor investigation (Asuni, Boutajangout, Quartermain, & Sigurdsson, 2007), the experimenting animal created disease causing environment related to tau more specifically in outer surface of cerebrum and

in limbic system. Subjects had been inoculated during 60–90 days of age, enforced 14days later and proceeded following month to month infusions. During 210-240 days, testing subjects were taken through 3 subjective experiments and dismissed at 240– 270 days among vaccinated creatures, tau directed medication diminished addition of phosphoryl group in tau and positively affect motor capability tau as well as psychological decay (Boutajangout et al., 2010). In the next report, a tiny chain of amino acids (Tau260–264 [pS262]) was used in tubiling adding area (Boutajangout et al., 2010), while the ones previously mentioned were situated on either side of this area (Boutajangout et al., 2010). In JNPL3 P301L mice, a strong immunizer reaction related to about two third lessen of addition of phosphoryl group to tau, motor system upgrading was backuped through direct medication (Boutajangout et al., 2010) concentrating on unusual upper surface of phosphoryl added tau might execute subgroups that could create outcomes for different immune materials followed by tau relaxation. New vaccine dependent systems focusing on tau are as a rule effectively added after in various creature models (Wisniewski & Sigurdsson, 2010), a clear indication for focusing on succeptable tau which might aggregate for the prevention of neuronal impairment and formation of nurofibrillary tangles (Kayed, 2010).

Table 2: Preclinical test of active vaccination (Panza et al., 2012)

Preclinical Study of Active vaccination triggering amyloid-β and Tau Protein			
Immunization process	**Immunogens/Epitops**	**Animal Model**	**Principle Findings**
Systemic active	Amyloid-beta 1–42	Amyloid precursor protein producing mice	Cerebral Ab reduced in young mice
Intranasal active	Amyloid-beta 1–40 and Amyloid-beta 1–42	Amyloid precursor protein producing mice	Cerebral Ab reduced
Intranasal active	Ab1–40 and Ab1–42	Amyloid precursor protein producing mice	Cerebral Ab reduced

Subcutaneous active	Ab1–42	APP/PS1 mice	Prevented memory loss
Systemic active	Antibody against aggregated Ab1–42	Tg2576 mice	Cerebral Ab reduced
Systemic active	Total chain of tau protein that is recombinant	Natural-type BL/6 rat	Increased NFT-like structures, axonal damage, gliosis and mononuclear infiltrate
Systemic active	Nonviral DNA vaccine	APP23 mice	Cerebral Ab reduced, with no inflammation
Systemic active	2 × Ab1–15	hAPP (FAD) mice	Cerebral Ab reduced, learning improved
Systemic active	Tau379–408 (pS396–pS404)	JNPL3 P301L mice	Decreased insoluble phosphorylated tau aggregates,improved performance on motor tasks
Immunization process	**Immunogens/Epitops**	**Animal Model**	**Principle Findings**
Systemic active	Ab1–11 fused with the promiscuous T-cell epitope	Tg2576 mice	Reduced insoluble, but not soluble, cerebral Ab
Systemic active	pMDC-3Ab1–11–PADRE construct	3 × Tg-AD mice	Reduced cerebral Ab, no glial activation, no microhemorrhage, improved behavior
Systemic active	Tau260–264 (pS262)	JNPL3 P301L mice	Decreased addition of phosphoryl group to tau in hippocumpus by side removal of tau and neuronal work improvement
Systemic active	Truncated tau protein	Tau-Tg rat	Delay of behavioral impairment and prevention of the development of NFTs

Systemic active	SDPM1 peptide that binds to Ab1–40/1–42-tetramers	APPswePSEN1(A246E) mice	Cerebral Ab reduced without inflammation, and improved cognition
Systemic active	Tau195–213[p202–205] +Tau207–220[p212–214] +Tau224–238[p231]	DM-tau-Tg mice	Decreased NFT high accumulation in CNS without encephalitogenicity ,no reported objection of neurons, negative effects within brain or any neuronal damage after administering for long time as well
Second generation systemic active	CAD106 - Anti-Ab1–6 antibody with Qb	APP23/APP24 mice	Cerebral Ab reduced with minimal potential side effects

Chapter 16 Passive Immunization

Inactive inoculation includes the organization of an immune response produced in another suitable condition that is stimulated before inducing into a patient. For AD, latent therapeutical approach could be an option which licenses more straightforward authority on degree of invulnerable reaction not in favor of Amyloid-β (Jicha, 2009)(Solfrizzi et al., n.d.). Latent external exchange of monoclonal Amyloid-β immunoglobulin appears most straightforward approach that keep distance from variety of antibodies that varied in Aβ-restricting properties (Jicha, 2009)(Morgan, 2006). The organical impacts happen during 1st day of drug delivery. Time turns highly insufficient than inspiring Th1-intervened autoimmunity. Promotion natural type rats given MAB amyloid-beta immunoglobulin demonstrated particuler huge lessening in CNS Amyloid-β condition, decreased cerebrum plaque formation and effects and shown betterment in sensitivity (Jicha, 2009)(Morgan, 2006). These advantageous impacts were watched utilizing basic evacuation present

cerebrum plaques (Lichtlen & Mohajeri, 2008). This finding proposes that inoculation procedures may work through instruments of Aβ restricting not obviously identified with clear SP evacuation. Statistically believed that readily solvent oligomer types Amyloid-β could go before plaque arrangement as well as in charge of neuritic demise thus influencing advancement of Alzheimer's pathogenesis (Walsh & Selkoe, 2004). Along these lines, withdrawal of these sort of oligomeric types of Amyloid-β might be useful for pathogenic procedure (Jicha, 2009). AD models display frameworks, passive vaccination shows up very protected (Lichtlen & Mohajeri, 2008). Significant wellbeing difficulties of this immuno remedial methodology are CNS monocyte derived cells, off track spiral activity and reduction of the counter acting agent into border drop wonder (Jicha, 2009). All things considered, around ten pathological investigations on inactive vaccination with different Amyloid-β antibodies under progressing (Solfrizzi et al., n.d.). The most exceptional aloof antibodies are bapineuzumab (AAB-001) (Kerchner & Boxer, 2010) and solanezumab (Samadi & Sultzer, 2020), Some humanized antibodies are in third stage clinical trials those are anti Aβ monoclonal in nature. There are 3 different types of amyloid-beta MAB have been shown which are authoritative to straight upper surface of amyloid-beta,

- Immunogens aligned with n-portion binding site [a.a -1-10]
- Targetting capital portion of Aβ [amino acids -17-32]
- Antibodies against C-portion binding site [amino acid-32-42] (Pul, Dodel, & Stangel, 2011).

Antibodies coordinated in the n-portion of Amyloid-β appeared for tying with Amyloid-β totals activating accumulated macrophages in brain by means of a Fc receptor-intervened component (Bard et al., 2000). They were additionally appeared for inducing hinderence in accumulation and harmful environment of Amyloid-β (Papers et al., 2007). F(ab')2 pieces that do not have the Fc locale of the counter acting agent may likewise be successful

(Lichtlen & Mohajeri, 2008)(Tamura et al., 2005). Bapineuzumab speaks to the proto-normal monoclonal counter acting agent coordinated negatively for the n-portion ending of Amyloid-β. This known as completely acculturated variant from rats mab of the mouse monoclonal counter acting agent 3D6 perceiving Amyloid-β1–5 locale (Tamura et al., 2005). Bapineuzumab is not reported to be cross-responded with Amyloid precursor protein and a-secretase cleavage of its own (sAPPa) (Tamura et al., 2005). In a consequent stage-2 investigation on bapineuzumab (half, one and two mg/kg), an adjusted aim for resolving examination, It was foun bapineuzumab- given person (n = 19) displayed decreased Carbon-eleven-marked Pittsburgh compound B (11C-PiB) maintenance on PET at year and a half contrasted and the standard, though the placebo treatment on people (n = 7) indicated growing consumption compared by the standard (Rinne et al., 2010). This information proposed that bapineuzumab diminished CNS amassing of Amyloid-β. Unwillingly, decrease inside cns Amyloid-β amassing in the persons given bapineuzumab went with a noteworthy subjective, useful and pharmacological advantage. Along these lines, the value of the 11C-PiB cerebrum take-up as biomarker of medication adequacy stays hazy, since we don't know whether a decrease in cerebrum Aβ stores may prompt clinical advantage. The nearest contender of bapineuzumab is solanezumab (LY2062430, Eli Lilly, Indianapolis, IN, USA) (Samadi & Sultzer, 2020). Solanezumab's instrument of activity differs with different therapeutical system. acculturated adaptation inside the rat neutralizer m266 coordinated in opponent to the Amyloid-b13– 28 area (Kresge, C. T., Leonowicz, M. E., Roth, W. J., Vartuli, J. C., Beck, 1992)(Siemers et al., 2010), perceives a particular upper surface binding portion in-between middle of a.a sequence and it can perceive different N-portion condensed types, for example, Amyloid-β3– 42 found randomly in Alzheimer’s senile plaques (Toledo, Shaw, & Trojanowski, 2013). Though bapineuzumab got more proclivity for deposited protein compared to solvent Amyloid-β, solanezumab specifically ties with dissolvable

Amyloid-β with practically zero fondness for the fibrillar structure (Seubert et al., 2008). Moreover, the inducement of solanezumab by stomach peritoneal route given rapid increment in the dimension of blood Amyloid-β, during interminable action with m266 though influenced Aβ affidavit, suggesting the modification of equilibrium of Amyloid-β presence between CNS and circulation, consequently quickening Amyloid-β flow (DeMattos et al., 2002). Subsequently, the site of neutralizer activity moves towards edge, there solvent types of Amyloid-β are separated towards edge dissemination and along these lines induce a flow of Amyloid-β from cerebrum to the circulating plasma, emerging a fringe drop for Amyloid-β leeway (DeMattos et al., 2002). Then again, the extended plasma Amyloid-β levels may be credited to a lessened breathing space rate of Amyloid-β complexed to antibodies, as no amyloid diminishing with m266 was observed (Seubert et al., 2008). Another perception demonstrated that regardless of an expansion in circulation of Amyloid-β, against Amyloid-β antibodies not altered the dimensions of absolute Amyloid-β (Levites et al., 2006). Yamada and associates exhibited that fringe organization of m266 really delay the flow transport of Amyloid-β from CNS to circulatory system as well as expands dimension of solvent single strand type of Amyloid-β in cerebrum (Yamada et al., 2009). These discoveries proposed that solanezumab might be powerful by balancing out Amyloid-β compound followed by averting arrangement of Amyloid-β polymer consisting of few monomers and amyloid accumulates (Yamada et al., 2009). Bapineuzumab and solanezumab have a few contenders, not more than 5 MAB are in different phases of advancement (Solfrizzi et al., n.d.).

Gantenerumab follows microglial phagocytosis process for the clearance of fibrils and aggregated amyloid-β, it is actually an IgG1 antibody but this has not enough study data. Extended studies showed that a higher dose of Gantenrumab is needed for the clinical outcomes; trial of this passive vaccine will ends up in 2023.Crenezumab is another MAB of humanized IgG4 type which has high binding possibilities to oligomeric and fibrillar

amyloid-β. Behavioral and cognition related changes are not experimented in mouse models, Crenezumab trial will be finished in 2022. Aducanumab is another MAB of human IgG1 type and it is taken from healthy and mature donors. The person whose immune system had properly fought against AD process, samples from them helps to find the proper vaccination for AD affected patients. In preclinical studies Aducanumab was able to lower both the soluble and insoluble amyloid-β through specific doses. Trial of Aucanumab will ends up in 2022 (Herline et al., 2018).

16.1 Tau Based Passive Immunization

Tau-based methodologies like immunogens against tau oligomer immunogens are like ones created targeting Amyloid-β (Kayed, 2010) might be perfect possibility for passive immunization (Kayed, 2010), giving energizing chances to approve against accumulates of tau immune therapy system among testing subjects officially accessible to specialists in current passed, coursing normal immune response which counter for tau (immunoglobulin M and immunoglobulin G) recognized within circulation and having few titers within cerebro spinal fluid (Rosenmann, Meiner, Geylis, Abramsky, & Steinitz, 2006). In circulation of 9 Alzheimer's disease patients and 8 sound people, within twenty Alzheimer's disease affected people as well as twenty-two models experiencing different neuronal scatter Rosenmann and partners discovered antibodies against non phosphorylated just as phosphoryl added tau. Like normally happening immunogen having negative activity for Amyloid-β, normally happening anti tau immunogen decline by increase of life (Pul et al., 2011). Another segment covering mab might act like mimicking ensuring focused on proteins against structural modification (Kontsekova, Ivanovova, Handzusova, & Novak, 2009). A few examinations have proposed that these antibodies adequately restrain conglomeration and danger of misfolded proteins (Solomon, 2003). During last few days, a different immune resizing approach have similerly proposed by utilizing similar antibodies focusing on miss-folded tau (Kontsekova et al.,

2009). These similar structural antibodies may encourage invivo collapsing as well as circumvent tau total, otherwise might invert obsessive adaptations to local. Cooperation's among antibodies and key epitopes may likewise kill harmfulness connected to misfolded tau (Kontsekova et al., 2009). The impacts of antibodies on protein collapsing are carefully substrate explicit; unique in relation to endogen structure that follow protein type structure (Solfrizzi et al., n.d.). Tau oligomer targeting immune approache might be in extra emphasis rather than amyloid-beta of extrscelluer and counter acting approaches for these two could be masked ,in all probability by endocytosis (Asuni et al., 2007). Antibodies and intrabodies with comparable explicitness will give significant devices for focusing oligomers of tau within rat models by inactive immunization for evaluating the job while occurrence of AD and other neuron degenerating infections.

Table 3: Preclinical test For passive vaccination (Solfrizzi et al., n.d.)

Preclinical Study of inactive vaccination focusing Amyloid-beta as well as Tau Protein in AD.			
Type of Immunization	**Immunogenes/Epitops**	**Animal Model**	**Principle Findings**
Systemic passive	Monoclonal: 10D5 or 21F12 Polyclonal: Ab1–42	PDAPP mice	Cerebral Ab reduced
Systemic passive	m266	PDAPP mice	Cerebral Ab reduced by altering CNS/plasma Ab clearance
Systemic passive	Anti-Ab3–6 antibody	APP23 mice	Cerebral Ab reduced with cerebral microhemorrhage
Systemic passive	m266	Tg2576 mice	Reversed memory deficit

Systemic passive	m266, 3D6 and 10D5	PDAPP mice	3D6 and 10D5, but not m266, increased CAA and microhemorrhage
Systemic passive	NAB61	Tg2576 mice	Cerebral Ab reduced, learning improved
Systemic passive	3D6 and m266	PDAPP mice	Reduced cerebral Ab but elevates vascular Ab and CAA
Systemic passive	m266	Tg2576 mice	Peripheral administration of m266 retards cerebral Ab clearance

Chapter 17 Methodology

Around two hundred journal articles related to different pathways of vaccinations and a variety of experimenting vaccines are studied through PubMed and Google Scholar. Only articles in English were searched for this review. The key words we used to search were, 'Alzheimer's Disease', 'Active vaccination', 'Passive vaccination'. In text citation and bibliographies were managed by using 'Mendeley' software.

Chapter 18 Discussion

It is considered that there is someone in every three second is getting affected by AD in the world. In 2015 there was an estimation of around 46.8 million people who were affected with AD. On the other side it was also assumed that this number might be increased to 50million within 2017. This number will be doubled in every 20 years, thus 75 million in 2030 and 131.6 million in 2050. On the other side it was assumed that It will mainly effect among developing countries. Intracellular amyloid plaques and extracellular tangles are the major cause of this disease. Though the pathophysiology of this disease is still unrecognized but

targeting on these sections, a variety of treatment methodologies are on trials. Research discoveries recommended that AD most likely includes a few physiological pathways; consequences of hostile to Aβ immunotherapy brought up the issue whether Aβ might be a perfect focus for AD treatment. Truth be told, while inoculation with preaggregated Aβ1– 42 (AN1792) brought about practically complete expulsion of the SPs from the cns of the AD patients, the evacuation of plaques did not avert dynamic psychological or clinical rot (Holmes et al., 2008). There are a few reasons why Aβ immunotherapy may have been insufficient in treating AD patients. Truth be told, other significant focuses in AD are the NFTs and their antecedents, made principally out of hyperphosphorylated tau proteins. Application overexpressing mice do show memory debilitation without tau pathology or neuronal misfortune, though the decrease of tau levels in APP-overexpressing mice averts Aβ-incited memory shortfalls (Roberson et al., 2007) Subsequently, a few changes in tau preceding NFT arrangement might be associated with memory disability. Be that as it may, these adjustments in tau might be deficient to cause NFT development and neuronal misfortune. Neurotic changes in tau that lead to NFT arrangement and neuronal misfortune might be critical to understanding why Aβ evacuation neglects to stop the clinical course of AD in people. In this way, it stays hazy whether treatments that just constrict Aβ pathology or tau pathology will be powerful in hindering the rate of intellectual and practical decrease in AD. By chance, Among the Aβ-based treatments, the most inventive methodology is spoken to by dynamic and uninvolved antibodies, which were demonstrated to bring down Aβ stores in the cerebrum of AD patients. Besides, among immunotherapeutics, the uninvolved methodology with hostile to Aβ monoclonal antibodies is the most progressive. Bapineuzumab and solanezumab speak to the front line of these inactive immunotherapy approaches and are by and by under broad clinical testing with more than 6000 AD patients in Phase III preliminaries. Subgroups investigations of the underlying Phase II ponder with

bapineuzumab recommend that the medication may have useful impacts in certain patients. Unfortunately, bapineuzumab treatment has been associated with the occurrence of vasogenic edema and brain microhemorrhages. It has been recommended that these dangers could be relieved amid the preclinical phases of AD before gigantic vascular Aβ accumulation happens. The speculation that Aβ is the key pathologic factor influencing the sickness procedure is firmly addressed by the finding that the evacuation of SPs with anti Aβ immunotherapy neglected to end dynamic neurodegeneration. These negative discoveries have been reverberated by the disappointment of semagacestat, a g-secretase inhibitor, in two expansive Phase III clinical preliminaries (Shankar et al., 2007), despite the fact that the medication drastically diminished the creation of Aβ in the CNS of people (Bateman et al., 2009). Recently planned clinical preliminaries that get to patients prior over the span of the ailment are in advancement (M. W. Weiner et al., 2010), also, new analytic criteria perceiving preclinical or prodromal/predementia AD will upgrade the capacity to test the amyloid course theory of AD in patients that may even now have the ability to react to treatment all the more decently. The immunotherapy cooperates with the human immuno system to kill the conglomeration procedure of Aβ species. As of now, it might be the best way to deal with adjusts the neurodegeneration and the subjective decrease present in AD. Regardless, more examinations are important to discover antibodies progressively explicit that don't evoke the immune system reaction. With respect to vaccination, the productivity of mAb to cross the blood-mind hindrance must be improved, just as the cross reactivity and the fiery adjustments saw in certain patients. It is likewise advantageous to meet the utilization of non-immunogenic mixes, for example, DNA or RNA aptamers, which are little oligonucleotide pieces with solid partiality to different targets running from little atoms to cells and can conquer the issues saw with the vaccination.

Chapter 19 Conclusion

The two major neuropathological indications of AD are SP and NFT. In the past generally amyloid (Aβ) peptide and the remainder of hyperphosphorylated tau protein were under concern. Very few examinations with respect to detached inoculation against tau protein are at present accessible. Human CNS imaging studies and posthumous neuropathological observations are about to have exhibited the capacity of both dynamic and inactive immunogens of Aβ immunotherapies to clear cerebrum Aβ stores. Second-stage dynamic Aβ antibodies and new uninvolved Aβ immunotherapies have been created and are under clinical testing. A few monoclonal antibodies created against Aβ, just as polyclonal antibodies, are at present in clinical testing. Some have just entered Phase III clinical preliminaries. The most developed Aβ monoclonal antibodies are bapineuzumab and solanezumab, which have been tried in Phase II preliminaries, where they diminished Aβ load in the cerebrum of AD patients. The consequences of progressing Phase III preliminaries with 6000 AD patients on bapineuzumab and solanezumab will let us know whether anti Aβ vaccination can change the course of this staggering infection.

Chapter 20 Future Work

A wide list of both active and passive vaccines is still under observation. Drugs that are under clinical experiments will show their results according to the designed model of pharmacological system. As AD accumulates a variety of physiological pathways for its development, getting positive response from a single type of immunotherapy is very tough. Different ongoing results could be merged together to achieve the target. Preclinical data is not good enough to make a combined drug delivery so in future it might be a section of interest that what type of clinical response could be found from the ongoing clinical trials. All the positive results could open a new window for further research and the development of the desired immunotherapy for diminishing AD.

References

Agadjanyan, M. G., Ghochikyan, A., Petrushina, I., Vasilevko, V., Movsesyan, N., Mkrtichyan, M., … Cribbs, D. H. (2005). Prototype Alzheimer's Disease Vaccine Using the Immunodominant B Cell Epitope from β-Amyloid and Promiscuous T Cell Epitope Pan HLA DR-Binding Peptide. *The Journal of Immunology*, *174*(3), 1580–1586. https://doi.org/10.4049/JIMMUNOL.174.3.1580

Akoachere, M. B., Schirmer, R. H., Gromer, S., Buchholz, K., Becker, K., Dandekar, T., & Eubel, J. K. (2007). Interactions of Methylene Blue with Human Disulfide Reductases and Their Orthologues from Plasmodium falciparum. *Antimicrobial Agents and Chemotherapy*, *52*(1), 183–191. https://doi.org/10.1128/aac.00773-07

Alkasir, R., Li, J., Li, X., Jin, M., & Zhu, B. (2017). Human gut microbiota: the links with dementia development. *Protein and Cell*, *8*(2), 90–102. https://doi.org/10.1007/s13238-016-0338-6

Alonso, A. C., Grundke-Iqbal, I., & Iqbal, K. (1996). Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. *Nature Medicine*, *2*(7), 783–787. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/8673924

Ando, K., Maruko-Otake, A., Ohtake, Y., Hayashishita, M., Sekiya, M., & Iijima, K. M. (2016). Stabilization of Microtubule-Unbound Tau via Tau Phosphorylation at Ser262/356 by Par-1/MARK Contributes to Augmentation of AD-Related Phosphorylation and Aβ42-Induced Tau Toxicity. *PLoS Genetics*, *12*(3), 1–28. https://doi.org/10.1371/journal.pgen.1005917

Andorfer, C. (2005). Cell-Cycle Reentry and Cell Death in Transgenic Mice Expressing Nonmutant Human Tau Isoforms. *Journal of Neuroscience*, *25*(22), 5446–5454.

https://doi.org/10.1523/JNEUROSCI.4637-04.2005

Asuni, A. A., Boutajangout, A., Quartermain, D., & Sigurdsson, E. M. (2007). Immunotherapy Targeting Pathological Tau Conformers in a Tangle Mouse Model Reduces Brain Pathology with Associated Functional Improvements. *Journal of Neuroscience*, *27*(34), 9115–9129. https://doi.org/10.1523/jneurosci.2361-07.2007

Bach, P., Tschape, J.-A., Kopietz, F., Braun, G., Baade, J. K., Wiederhold, K.-H., … Muller, U. C. (2009). Vaccination with A -Displaying Virus-Like Particles Reduces Soluble and Insoluble Cerebral A and Lowers Plaque Burden in APP Transgenic Mice. *The Journal of Immunology*, *182*(12), 7613–7624. https://doi.org/10.4049/jimmunol.0803366

Bard, F., Cannon, C., Barbour, R., Burke, R. L., Games, D., Grajeda, H., … Yednock, T. (2000). Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. *Nature Medicine*, *6*(8), 916–919. https://doi.org/10.1038/78682

Barrera-Ocampo, A., & Lopera, F. (2016). Amyloid-beta immunotherapy: the hope for Alzheimer disease? *Colombia Medica (Cali, Colombia)*, *47*(4), 203–212. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/28293044

Bateman, R. J., Siemers, E. R., Mawuenyega, K. G., Wen, G., Browning, K. R., Sigurdson, W. C., … Holtzman, D. M. (2009). A γ-secretase inhibitor decreases amyloid-β production in the central nervous system. *Annals of Neurology*, *66*(1), 48–54. https://doi.org/10.1002/ana.21623

Boimel, M., Grigoriadis, N., Lourbopoulos, A., Haber, E., Abramsky, O., & Rosenmann, H. (2010). Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. *Experimental Neurology*, *224*(2), 472–485. https://doi.org/10.1016/j.expneurol.2010.05.010

Boimel, M., Ovadia, H., Karussis, D., Touloumi, O., Rosenmann, H., Grigoriadis, N., & Abramsky, O. (2006). Tauopathy-like Abnormalities and Neurologic Deficits in Mice Immunized With Neuronal Tau Protein. *Archives of Neurology*, *63*(10), 1459. https://doi.org/10.1001/archneur.63.10.1459

Boutajangout, A., Quartermain, D., & Sigurdsson, E. M. (2010). Immunotherapy Targeting Pathological Tau Prevents Cognitive Decline in a New Tangle Mouse Model. *Journal of Neuroscience*, *30*(49), 16559–16566. https://doi.org/10.1523/jneurosci.4363-10.2010

Boxer, A. L., Lang, A. E., Grossman, M., Knopman, D. S., Miller, B. L., Schneider, L. S., … Morimoto, B. H. (2014). Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. *The Lancet Neurology*, *13*(7), 676–685. https://doi.org/10.1016/S1474-4422(14)70088-2

Bu, G., Liu, C., & Kanekiyo, T. (2013). Vascular hypothesis of Alzheimer ' s disease : role of apoE and apoE receptors. *Molecular Neurodegeneration*, *8*(Suppl 1), O20. https://doi.org/10.1186/1750-1326-8-S1-O20

Bulic, B., Pickhardt, M., Khlistunova, I., Biernat, J., Mandelkow, E. M., Mandelkow, E., & Waldmann, H. (2007). Rhodanine-based tau aggregation inhibitors in cell models of tauopathy. *Angewandte Chemie - International Edition*, *46*(48), 9215–9219. https://doi.org/10.1002/anie.200704051

Bulic, B., Pickhardt, M., Mandelkow, E. M., & Mandelkow, E. (2010). Tau protein and tau aggregation inhibitors. *Neuropharmacology*, *59*(4–5), 276–289. https://doi.org/10.1016/j.neuropharm.2010.01.016

Carter, C. J. (2017). Genetic, Transcriptome, Proteomic, and Epidemiological Evidence for Blood-Brain Barrier Disruption and Polymicrobial Brain Invasion as Determinant Factors in Alzheimer's Disease. *Journal of Alzheimer's Disease Reports*, *1*(1), 125–157.

https://doi.org/10.3233/ADR-170017

Clark, C. M., Xie, S., Chittams, J., Ewbank, D., Peskind, E., Galasko, D., … Weitlauf, S. L. (2003). Cerebrospinal Fluid Tau and ß-Amyloid. *Archives of Neurology*, *60*, 1696–1702. https://doi.org/10.1001/archneur.60.12.1696

Clavaguera, F., Akatsu, H., Fraser, G., Crowther, R. A., Frank, S., Hench, J., … Tolnay, M. (2013). Brain homogenates from human tauopathies induce tau inclusions in mouse brain. *Proceedings of the National Academy of Sciences*, *110*(23), 9535–9540. https://doi.org/10.1073/pnas.1301175110

Close, H., We, A., & Janus, C. (2003). Vaccines for Alzheimer ' s Disease, *17*(7), 457–474.

Cohen, T. J., Guo, J. L., Hurtado, D. E., Kwong, L. K., Mills, I. P., Trojanowski, J. Q., & Lee, V. M. Y. (2011). The acetylation of tau inhibits its function and promotes pathological tau aggregation. *Nature Communications*, *2*(1), 252–259. https://doi.org/10.1038/ncomms1255

Corsetti, V., Amadoro, G., Gentile, A., Capsoni, S., Ciotti, M. T., Cencioni, M. T., … Calissano, P. (2008). Identification of a caspase-derived N-terminal tau fragment in cellular and animal Alzheimer's disease models. *Molecular and Cellular Neuroscience*, *38*(3), 381–392. https://doi.org/10.1016/j.mcn.2008.03.011

Costerton, J. W., Calkwell, D. E., Kober, D. R., M.Lappin-Scott, H., Lewandowski, Z., Caldwell, D. E., … Lappin-Scott, H. M. (1995). Microbial Biofilms. *Annual Review of Microscopy*, *49*, 711–745.

Davtyan, H., Bacon, A., Petrushina, I., Zagorski, K., Cribbs, D. H., Ghochikyan, A., & Agadjanyan, M. G. (2014). Immunogenicity of DNA- and recombinant protein-based Alzheimer disease epitope vaccines. *Human Vaccines and Immunotherapeutics*, *10*(5),

1248–1255. https://doi.org/10.4161/hv.27882

De Calignon, A., Spires-Jones, T. L., Pitstick, R., Carlson, G. A., & Hyman, B. T. (2009). Tangle-bearing neurons survive despite disruption of membrane integrity in a mouse model of tauopathy. *Journal of Neuropathology and Experimental Neurology*, *68*(7), 757–761. https://doi.org/10.1097/NEN.0b013e3181a9fc66

de la Torre, J. C. (2002). Alzheimer Disease as a Vascular Disorder. *Stroke*, *33*(4), 1152–1162. https://doi.org/10.1161/01.STR.0000014421.15948.67

Del C. Alonso, A., Zaidi, T., Novak, M., Barra, H. S., Grundke-Iqbal, I., & Iqbal, K. (2001). Interaction of Tau Isoforms with Alzheimer's Disease Abnormally Hyperphosphorylated Tau and in Vitro Phosphorylation into the Disease-like Protein. *Journal of Biological Chemistry*, *276*(41), 37967–37973. https://doi.org/10.1074/jbc.M105365200

DeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J.-C., Paul, S. M., & Holtzman, D. M. (2002). Peripheral anti-A antibody alters CNS and plasma A clearance and decreases brain A burden in a mouse model of Alzheimer's disease. *Proceedings of the National Academy of Sciences*, *98*(15), 8850–8855. https://doi.org/10.1073/pnas.151261398

Donoghue, S., Paterson, K. R., Jenkins, L., Bullock, R., Millais, S. B., Bayer, A. J., … Jones, R. W. (2011). Evaluation of the safety and immunogenicity of synthetic A 42 (AN1792) in patients with AD. *Neurology*, *64*(1), 94–101. https://doi.org/10.1212/01.wnl.0000148604.77591.67

Ferrari, A., Hoerndli, F., Baechi, T., Nitsch, R. M., & Götz, J. (2003). B-Amyloid Induces Paired Helical Filament-Like Tau Filaments in Tissue Culture. *Journal of Biological Chemistry*, *278*(41), 40162–40168. https://doi.org/10.1074/jbc.M308243200

Ferrer, I., Rovira, M. B., Guerra, M. L. S., Rey, M. J., & Costa-Jussá, F. (2006). Neuropathology and Pathogenesis of Encephalitis following Amyloid β Immunization in Alzheimer's Disease. *Brain Pathology*, *14*(1), 11–20. https://doi.org/10.1111/j.1750-3639.2004.tb00493.x

Fisher, Y., Nemirovsky, A., Baron, R., & Monsonego, A. (2010). T cells specifically targeted to amyloid plaques enhance plaque clearance in a mouse model of Alzheimer's disease. *PloS One*, *5*(5), e10830. https://doi.org/10.1371/journal.pone.0010830

Frazer, M. E., Hughes, J. E., Mastrangelo, M. A., Tibbens, J. L., Federoff, H. J., & Bowers, W. J. (2008). Reduced pathology and improved behavioral performance in Alzheimer's disease mice vaccinated with HSV amplicons expressing amyloid-beta and interleukin-4. *Molecular Therapy : The Journal of the American Society of Gene Therapy*, *16*(5), 845. https://doi.org/10.1038/MT.2008.39

Frenkel, D., Dewachter, I., Van Leuven, F., & Solomon, B. (2003). Reduction of β-amyloid plaques in brain of transgenic mouse model of Alzheimer's disease by EFRH-phage immunization. *Vaccine*, *21*(11–12), 1060–1065. https://doi.org/10.1016/S0264-410X(02)00609-6

Frenkel, D., Puckett, L., Petrovic, S., Xia, W., Chen, G., Vega, J., … Weiner, H. L. (2008). A nasal proteosome adjuvant activates microglia and prevents amyloid deposition. *Annals of Neurology*, *63*(5), 591–601. https://doi.org/10.1002/ana.21340

Frey, P., Jacobson, L. H., Bachmann, M. F., Staufenbiel, M., Reichwald, J., Ortmann, R., … Luond, R. (2011). The Second-Generation Active A Immunotherapy CAD106 Reduces Amyloid Accumulation in APP Transgenic Mice While Minimizing Potential Side Effects. *Journal of Neuroscience*, *31*(25), 9323–9331. https://doi.org/10.1523/jneurosci.0293-11.2011

Gamblin, T. C., Chen, F., Zambrano, A., Abraha, A., Lagalwar, S., Guillozet, A. L., … Cryns, V. L. (2003). Caspase cleavage of tau: Linking amyloid and neurofibrillary tangles in Alzheimer's disease. *Proceedings of the National Academy of Sciences*, *100*(17), 10032–10037. https://doi.org/10.1073/pnas.1630428100

Goedert, M., & Spillantini, M. G. (2000). Tau mutations in frontotemporal dementia FTDP-17 and their relevance for Alzheimer's disease. *Biochimica et Biophysica Acta - Molecular Basis of Disease*, *1502*(1), 110–121. https://doi.org/10.1016/S0925-4439(00)00037-5

Golde, T. E., Petrucelli, L., & Lewis, J. (2010). Targeting Abeta and tau in Alzheimer's disease, an early interim report. *Experimental Neurology*, *223*(2), 252–266. https://doi.org/10.1016/j.expneurol.2009.07.035

Götz, J., Chen, F., Van Dorpe, J., & Nitsch, R. M. (2001). Formation of neurofibrillary tangles in P301L tau transgenic mice induced by Aβ42 fibrils. *Science*, *293*(5534), 1491–1495. https://doi.org/10.1126/science.1062097

Grill, J. D., & Cummings, J. L. (2010). Current therapeutic targets for the treatment of Alzheimer's disease. *Expert Review of Neurotherapeutics*, *10*(5), 711–728. https://doi.org/10.1586/ern.10.29

Grill, J. D., & Cummings, J. L. (2016). Expert Review of Neurotherapeutics Alzheimer ' s disease Current therapeutic targets for the treatment of Alzheimer ' s disease, *7175*(December). https://doi.org/10.1586/ern.10.29

Guo, J.-P., Arai, T., Miklossy, J., & McGeer, P. L. (2006). Abeta and tau form soluble complexes that may promote self aggregation of both into the insoluble forms observed in Alzheimer's disease. *Proceedings of the National Academy of Sciences*, *103*(6), 1953–1958. https://doi.org/10.1073/pnas.0509386103

Haass, C., & Selkoe, D. J. (2007). Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid β-peptide. *Nature Reviews Molecular Cell Biology*, *8*(2), 101–112. https://doi.org/10.1038/nrm2101

Hanger, D. P., Anderton, B. H., & Noble, W. (2009). Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. *Trends in Molecular Medicine*, *15*(3), 112–119. https://doi.org/10.1016/j.molmed.2009.01.003

Härtig, W., Stieler, J., Boerema, A. S., Wolf, J., Schmidt, U., Weißfuß, J., … Arendt, T. (2007). Hibernation model of tau phosphorylation in hamsters: Selective vulnerability of cholinergic basal forebrain neurons - Implications for Alzheimer's disease. *European Journal of Neuroscience*, *25*(1), 69–80. https://doi.org/10.1111/j.1460-9568.2006.05250.x

Herline, K., Drummond, E., & Wisniewski, T. (2018). Recent advancements toward therapeutic vaccines against Alzheimer's disease. *Expert Review of Vaccines*, *17*(8), 707–721. https://doi.org/10.1080/14760584.2018.1500905

Hock, C., Konietzko, U., Streffer, J. R., Tracy, J., Signorell, A., Lemke, U., … Strasse, A. F. (2003). <1-s2.0-S0896627303002940-main.pdf>, *38*, 547–554.

Höglinger, G. U., Schöpe, J., Stamelou, M., Kassubek, J., del Ser, T., Boxer, A. L., … Huppertz, H.-J. (2017). Longitudinal magnetic resonance imaging in progressive supranuclear palsy: A new combined score for clinical trials. *Movement Disorders*, *32*(6), 842–852. https://doi.org/10.1002/mds.26973

Holmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., … Nicoll, J. A. (2008). Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. *The Lancet*, *372*(9634), 216–223. https://doi.org/10.1016/S0140-6736(08)61075-2

Holtzman, D. M., Carrillo, M. C., Hendrix, J. A., Bain, L. J., Catafau, A. M., Gault, L. M., … Hutton, M. (2016). Tau: From research to clinical development. *Alzheimer's and Dementia*, *12*(10), 1033–1039. https://doi.org/10.1016/j.jalz.2016.03.018

HUTTON, M. (2010). Molecular Genetics of Chromosome 17 Tauopathies. *Annals of the New York Academy of Sciences*, *920*(1), 63–73. https://doi.org/10.1111/j.1749-6632.2000.tb06906.x

Hutton, M., Lewis, J., McGowan, E., Rockwood, J., Melrose, H., Nacharaju, P., … Davies, P. (2000). Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. *Nature Genetics*, *25*(4), 402–405. https://doi.org/10.1038/78078

Ingelsson, M., Fukumoto, H., Newell, K. L., Growdon, J. H., Hedley-Whyte, E. T., Frosch, M. P., … Irizarry, M. C. (2004). Early Aβ accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. *Neurology*, *62*(6), 925–931. https://doi.org/10.1212/01.WNL.0000115115.98960.37

Itzhaki, R. F. (2017). Herpes and Alzheimer's disease: Subversion in the central nervous system and how it might be halted. *Handbook of Infection and Alzheimer's Disease*, *54*, 199–207. https://doi.org/10.3233/978-1-61499-706-199

Itzhaki, R. F., Lathe, R., Balin, B. J., Ball, M. J., Bearere, E. L., Braak, H., … Whittum-Hudson, J. A. (2017). Microbes and Alzheimer's disease. *Handbook of Infection and Alzheimer's Disease*, *51*, 3–8. https://doi.org/10.3233/978-1-61499-706-3

Iwatsubo, T., Masuda, M., Suzuki, N., Hasegawa, M., Goedert, M., Nonaka, T., … Hisanaga, S. (2006). Small Molecule Inhibitors of α-Synuclein Filament Assembly † . *Biochemistry*, *45*(19), 6085–6094. https://doi.org/10.1021/bi0600749

Jicha, G. A. (2009). Is passive immunization for Alzheimer's disease 'alive and well' or 'dead and buried'? *Expert Opinion on Biological Therapy*, *9*(4), 481–491. https://doi.org/10.1517/14712590902828285

Johnson, G. V. W., Seubert, P., Cox, T. M., Motter, R., Brown, J. P., & Galasko, D. (2002). The τ Protein in Human Cerebrospinal Fluid in Alzheimer's Disease Consists of Proteolytically Derived Fragments. *Journal of Neurochemistry*, *68*(1), 430–433. https://doi.org/10.1046/j.1471-4159.1997.68010430.x

K., B., H., Z., & A.M., F. (2012). Fluid biomarkers in Alzheimer disease. *Cold Spring Harbor Perspectives in Medicine*, *2*(9). Retrieved from http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L370150994%5Cnhttp://dx.doi.org/10.1101/cshperspect.a006221%5Cnhttp://linksource.ebsco.com/linking.aspx?sid=EMBASE&issn=21571422&id=doi:10.1101%2Fcshperspect.a006221&atitle=Fluid+bio

Kaufman, S. K., Sanders, D. W., Thomas, T. L., Ruchinskas, A. J., Vaquer-Alicea, J., Sharma, A. M., … Diamond, M. I. (2016). Tau Prion Strains Dictate Patterns of Cell Pathology, Progression Rate, and Regional Vulnerability In Vivo. *Neuron*, *92*(4), 796–812. https://doi.org/10.1016/j.neuron.2016.09.055

Kayed, R. (2010). Anti-tau oligomers passive vaccination for the treatment of Alzheimer disease. *Human Vaccines*, *6*(11), 931–935. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/20980799

Kenessey, A., & Yen, S. H. C. (1993). The extent of phosphorylation of fetal tau is comparable to that of PHF-tau from Alzheimer paired helical filaments. *Brain Research*, *629*(1), 40–46. https://doi.org/10.1016/0006-8993(93)90478-6

Kerchner, G. A., & Boxer, A. L. (2010). Bapineuzumab, 1121–1130.

Kimura, T., Fukuda, T., Sahara, N., Yamashita, S., Murayama, M., Mizoroki, T., … Takashima, A. (2010). Aggregation of detergent-insoluble tau is involved in neuronal loss but not in synaptic loss. *Journal of Biological Chemistry*, *285*(49), 38692–38699. https://doi.org/10.1074/jbc.M110.136630

Kontsekova, E., Ivanovova, N., Handzusova, M., & Novak, M. (2009). Chaperone-like antibodies in neurodegenerative tauopathies: implication for immunotherapy. *Cellular and Molecular Neurobiology*, *29*(6–7), 793–798. https://doi.org/10.1007/S10571-009-9355-9

Kresge, C. T., Leonowicz, M. E., Roth, W. J., Vartuli, J. C., Beck, J. S. (1992). ²»ÉøÍ¸ÐÔµÄ © 19 9 2 Nature Publishing Group. *Nature*, *359*, 710–713.

LEMERE, C. A., MARON, R., SPOONER, E. T., GRENFELL, T. J., MORI, C., DESAI, R., … SELKOE, D. J. (2010). Nasal Aβ Treatment Induces Anti-Aβ Antibody Production and Decreases Cerebral Amyloid Burden in PD-APP Mice. *Annals of the New York Academy of Sciences*, *920*(1), 328–331. https://doi.org/10.1111/j.1749-6632.2000.tb06943.x

Lemere, C. A., & Masliah, E. (2010a). Can Alzheimer disease be prevented by amyloid-beta immunotherapy? *Nature Reviews. Neurology*, *6*(2), 108–119. https://doi.org/10.1038/nrneurol.2009.219

Lemere, C. A., & Masliah, E. (2010b). Can Alzheimer disease be prevented by amyloid-B immunotherapy? *Nature Reviews Neurology*, *6*(2), 108–119. https://doi.org/10.1038/nrneurol.2009.219

Levites, Y., Smithson, L. A., Price, R. W., Dakin, R. S., Yuan, B., Sierks, M. R., … Golde, T. E. (2006). Insights into the mechanisms of action of anti-Aβ antibodies in Alzheimer's disease mouse models. *The FASEB Journal*, *20*(14), 2576–2578.

https://doi.org/10.1096/fj.06-6463fje

Lichtlen, P., & Mohajeri, M. H. (2008). Antibody-based approaches in Alzheimer's research: Safety, pharmacokinetics, metabolism, and analytical tools. *Journal of Neurochemistry*, *104*(4), 859–874. https://doi.org/10.1111/j.1471-4159.2007.05064.x

Lindwall, G., & Cole, R. D. (1984). Phosphorylation affects the ability of tau protein to promote microtubule assembly. *The Journal of Biological Chemistry*, *259*(8), 5301–5305. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/6425287

Lövheim, H., Olsson, J., Weidung, B., Johansson, A., Eriksson, S., Hallmans, G., & Elgh, F. (2018). Interaction between Cytomegalovirus and Herpes Simplex Virus Type 1 Associated with the Risk of Alzheimer's Disease Development. *Journal of Alzheimer's Disease*, *61*(3), 939–945. https://doi.org/10.3233/JAD-161305

Maeda, S., & Takashima, A. (2007). Granular Tau Oligomers as Intermediates of Tau Filaments Supporting information, *000023*, 2–5.

Mandelkow, E.-M., & Mandelkow, E. (2012). Biochemistry and cell biology of tau protein in neurofibrillary degeneration. *Cold Spring Harbor Perspectives in Medicine*, *2*(7), a006247. https://doi.org/10.1101/cshperspect.a006247

Mandelkow, E., Godemann, R., Stamer, K., Baumann, K., Preuss, U., Trinczek, B., … Illenberger, S. (2013). The Endogenous and Cell Cycle-dependent Phosphorylation of tau Protein in Living Cells: Implications for Alzheimer's Disease. *Molecular Biology of the Cell*, *9*(6), 1495–1512. https://doi.org/10.1091/mbc.9.6.1495

Mayeux, R., & Stern, Y. (2012). Epidemiology of Alzheimer disease. *Cold Spring Harbor Perspectives in Medicine*, *2*(8). https://doi.org/10.1101/cshperspect.a006239

McGeer, P. L., & McGeer, E. G. (2013). The amyloid cascade-inflammatory hypothesis of

Alzheimer disease: Implications for therapy. *Acta Neuropathologica*, *126*(4), 479–497. https://doi.org/10.1007/s00401-013-1177-7

Medina, M. (2011). Recent Developments in Tau-Based Therapeutics for Neurodegenerative Diseases. *Recent Patents on CNS Drug Discovery*, *6*(1), 20–30. https://doi.org/10.2174/157488911794079091

Michel, B. F., Frank, A., Puel, M., Gilman, S., Hock, C., Laurent, B., … Dartigues, J.-F. (2012). Subacute meningoencephalitis in a subset of patients with AD after A 42 immunization. *Neurology*, *61*(1), 46–54. https://doi.org/10.1212/01.wnl.0000073623.84147.a8

Miklossy, Judit. (2012). Common Mechanisms Involved in Alzheimer's Disease and Type 2 diabetes: A Key Role for Local Bacterial Infection and Inflammation? *Preprint*, *8*(4), 1–29. Retrieved from message:%3C595470AF-AD76-415B-84AC-9FF2A532B852@HELIX.MGH.HARVARD.EDU%3E

Miklossy, Judith. (2016). Bacterial Amyloid and DNA are Important Constituents of Senile Plaques: Further Evidence of the Spirochetal and Biofilm Nature of Senile Plaques. *Journal of Alzheimer's Disease : JAD*, *53*(4), 1459–1473. https://doi.org/10.3233/JAD-160451

Miller, Y., Ma, B., & Nussinov, R. (2011). Synergistic interactions between repeats in tau protein and Aβ amyloids may be responsible for accelerated aggregation via polymorphic States. *Biochemistry*, *50*(23), 5172–5181. https://doi.org/10.1021/bi200400u

Min, S. W., Chen, X., Tracy, T. E., Li, Y., Zhou, Y., Wang, C., … Gan, L. (2015). Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits. *Nature Medicine*, *21*(10), 1154–1162. https://doi.org/10.1038/nm.3951

Min, S. W., Cho, S. H., Zhou, Y., Schroeder, S., Haroutunian, V., Seeley, W. W., … Gan, L. (2010). Acetylation of tau inhibits its degradation and contributes to tauopathy. *Neuron*, *67*(6), 953–966. https://doi.org/10.1016/j.neuron.2010.08.044

Morgan, D. (2006). Mechanisms of Aβ plaque clearance following passive Aβ immunization. *Neurodegenerative Diseases*, *2*(5), 261–266. https://doi.org/10.1159/000090366

Movsesyan, N., Ghochikyan, A., Mkrtichyan, M., Petrushina, I., Davtyan, H., Olkhanud, P. B., … Agadjanyan, M. G. (2008). Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine - A novel immunotherapeutic strategy. *PLoS ONE*, *3*(5). https://doi.org/10.1371/journal.pone.0002124

Muhs, A., Hickman, D. T., Pihlgren, M., Chuard, N., Giriens, V., Meerschman, C., … Nicolau, C. (2007). Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice. *Proceedings of the National Academy of Sciences*, *104*(23), 9810–9815. https://doi.org/10.1073/pnas.0703137104

Müller, U. C., Deller, T., & Korte, M. (2017). Not just amyloid: Physiological functions of the amyloid precursor protein family. *Nature Reviews Neuroscience*, *18*(5), 281–298. https://doi.org/10.1038/nrn.2017.29

Natrajan, R., Shiu, K. K., Lambros, M. B. K., Rodriguez-pinilla, S. M., Tan, D. S. P., Lord, C. J., & Marchi, C. (2008). The genomic profile of HER2-amplified breast cancers : the influence of ER status. *Journal of Pathology*, *216*(July), 399–407. https://doi.org/10.1002/path

Necula, M., Chirita, C. N., & Kuret, J. (2005). Cyanine dye N744 inhibits tau fibrillization by blocking filament extension: implications for the treatment of tauopathic neurodegenerative diseases. *Biochemistry*, *44*(30), 10227–10237.

https://doi.org/10.1021/bi050387o

Neuroimmunology Drug Development - Neuroimmunology Drug Development Summit (NIDD). (n.d.). Retrieved February 25, 2019, from https://neuroimmunology-drugdevelopment.com/?gclid=Cj0KCQiAwc7jBRD8ARIsAKSUBHJSmuLfCcfNhmGRen-RC55F7om9s0j9e-0zyUQWyLq04x3P87LrdbIaAiLuEALw_wcB

Nizynski, B., Dzwolak, W., & Nieznanski, K. (2017). Amyloidogenesis of Tau protein. *Protein Science*, *26*(11), 2126–2150. https://doi.org/10.1002/pro.3275

No Secular Trend and High Variability for Adas-Cog Change Among Placebo. (n.d.), 3100603.

Novak, M., Kabat, J., & Wischik, C. M. (1993). Molecular characterization of the minimal protease resistant tau unit of the Alzheimer's disease paired helical filament. *The EMBO Journal*, *12*(1), 365–370. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/7679073

Oddo, S., Billings, L., Kesslak, J. P., Cribbs, D. H., & Laferla, F. M. (2015). Google Developers | Picker API Developer's Guide | Picker. *Google Developers*, *43*, 321–332. https://doi.org/10.1016/j.neuron.2004.07.003

Okura, Y., Miyakoshi, A., Kohyama, K., Park, I.-K., Staufenbiel, M., & Matsumoto, Y. (2006). Nonviral Abeta DNA vaccine therapy against Alzheimer's disease: Long-term effects and safety. *Proceedings of the National Academy of Sciences*, *103*(25), 9619–9624. https://doi.org/10.1073/pnas.0600966103

Panza, F., Frisardi, V., Imbimbo, B. P., Seripa, D., Solfrizzi, V., & Pilotto, A. (2011). Monoclonal antibodies against β-amyloid (Aβ) for the treatment of Alzheimer's disease: the Aβ target at a crossroads. *Expert Opinion on Biological Therapy*, *11*(6), 679–686. https://doi.org/10.1517/14712598.2011.579099

Panza, F., Frisardi, V., Solfrizzi, V., Imbimbo, B. P., Logroscino, G., Santamato, A., … Pilotto, A. (2012). Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies. *Immunotherapy*, *4*(2), 213–238. https://doi.org/10.2217/imt.11.170

Papers, J. B. C., M, D. O. I., Mamikonyan, G., Necula, M., Mkrtichyan, M., Ghochikyan, A., … Agadjanyan, M. G. (2007). Anti-A 1 – 11 Antibody Binds to Different -Amyloid Species , Inhibits Fibril Formation , and Disaggregates Preformed Fibrils but Not the Most Toxic Oligomers *. *Journal of Biological Chemistry*, *282*(31), 22376–22386. https://doi.org/10.1074/jbc.M700088200

Petkova, A. T., Leapman, R. D., Guo, Z., Yau, W. M., Mattson, M. P., & Tycko, R. (2005). Self-propagating, molecular-level polymorphism in Alzheimer's β-amyloid fibrils. *Science*, *307*(5707), 262–265. https://doi.org/10.1126/science.1105850

Pickhardt, M., Biernat, J., Khlistunova, I., Wang, Y.-P., Gazova, Z., Mandelkow, E.-M., & Mandelkow, E. (2007). N-phenylamine derivatives as aggregation inhibitors in cell models of tauopathy. *Current Alzheimer Research*, *4*(4), 397–402. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/17908042

Piggybac Transgenic Mouse Services | Cyagen Biosciences APAC. (n.d.). Retrieved February 25, 2019, from https://apac.cyagen.com/service/piggybac-transgenic-mice.html?gclid=Cj0KCQiAwc7jBRD8ARIsAKSUBHKBes06Cga_C0Ytaz-2MXLQbMQuquEEmdxan1dIIkvdqZfg5otjAQgaAr1YEALw_wcB

Pisa, Di., Alonso, R., Fernández-Fernández, A. M., Rábano, A., & Carrasco, L. (2017). Polymicrobial Infections in Brain Tissue from Alzheimer's Disease Patients. *Scientific Reports*, *7*(1), 1–14. https://doi.org/10.1038/s41598-017-05903-y

Presenilin I Protein - Alzheimer's Disease:the influence of presenilin I. (n.d.). Retrieved April 19, 2019, from http://cortezgen564s15.weebly.com/presenilin-i-protein.html

Pride, M., Seubert, P., Grundman, M., Hagen, M., Eldridge, J., & Black, R. S. (2008). Progress in the Active Immunotherapeutic Approach to Alzheimer's Disease: Clinical Investigations into AN1792-Associated Meningoencephalitis. *Neurodegenerative Diseases*, *5*(3–4), 194–196. https://doi.org/10.1159/000113700

Prince, M., Wimo, A., Guerchet, M., Ali, G. C., Wu, Y. T., & Prina, M. (2015). World Alzheimer Report 2015. London, UK. *Alzheimer's Disease International*, 1–92. https://doi.org/10.1111/j.0963-7214.2004.00293.x

Pul, R., Dodel, R., & Stangel, M. (2011). Antibody-based therapy in Alzheimer ' s disease, 343–357.

Rahman, M. R., Tajmim, A., Ali, M., & Sharif, M. (2017). Overview and Current Status of Alzheimer's Disease in Bangladesh. *Journal of Alzheimer's Disease Reports*, *1*(1), 27–42. https://doi.org/10.3233/ADR-170012

Rinne, J. O., Brooks, D. J., Rossor, M. N., Fox, N. C., Bullock, R., Klunk, W. E., … Grundman, M. (2010). 11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. *The Lancet Neurology*, *9*(4), 363–372. https://doi.org/10.1016/S1474-4422(10)70043-0

Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T., … Mucke, L. (2007). Reducing endogenous tau ameliorates amyloid ??-induced deficits in an Alzheimer's disease mouse model. *Science*, *316*(5825), 750–754. https://doi.org/10.1126/science.1141736

Rosenmann, H., Grigoriadis, N., Eldar-Levy, H., Avital, A., Rozenstein, L., Touloumi, O., … Abramsky, O. (2008). A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics. *Experimental Neurology*, *212*(1), 71–84. https://doi.org/10.1016/j.expneurol.2008.03.007

Rosenmann, H., Meiner, Z., Geylis, V., Abramsky, O., & Steinitz, M. (2006). Detection of circulating antibodies against tau protein in its unphosphorylated and in its neurofibrillary tangles-related phosphorylated state in Alzheimer's disease and healthy subjects. *Neuroscience Letters*, *410*(2), 90–93. https://doi.org/10.1016/j.neulet.2006.01.072

Sahara, N., Maeda, S., Murayama, M., Suzuki, T., Dohmae, N., Yen, S. H., & Takashima, A. (2007). Assembly of two distinct dimers and higher-order oligomers from full-length tau. *European Journal of Neuroscience*, *25*(10), 3020–3029. https://doi.org/10.1111/j.1460-9568.2007.05555.x

Samadi, H., & Sultzer, D. (2020). Solanezumab for Alzheimer ' s disease, 787–798.

Santacruz, K., Lewis, J., Spires, T., Paulson, J., Kotilinek, L., Ingelsson, M., … Ashe, K. H. (2005). Medicine: Tau suppression in a neurodegenerative mouse model improves memory function. *Science*, *309*(5733), 476–481. https://doi.org/10.1126/science.1113694

Schneider, A., & Mandelkow, E. (2008). Tau-Based Treatment Strategies in Neurodegenerative Diseases. *Neurotherapeutics*, *5*(3), 443–457. https://doi.org/10.1016/j.nurt.2008.05.006

Seubert, P., Barbour, R., Khan, K., Motter, R., Tang, P., Kholodenko, D., … Games, D. (2008). Antibody capture of soluble Aβ does not reduce cortical Aβ amyloidosis in the PDAPP mouse. *Neurodegenerative Diseases*, *5*(2), 65–71.

https://doi.org/10.1159/000112834

Shankar, G. M., Bloodgood, B. L., Townsend, M., Walsh, D. M., Selkoe, D. J., & Sabatini, B. L. (2007). Natural Oligomers of the Alzheimer Amyloid- Protein Induce Reversible Synapse Loss by Modulating an NMDA-Type Glutamate Receptor-Dependent Signaling Pathway. *Journal of Neuroscience*, *27*(11), 2866–2875. https://doi.org/10.1523/JNEUROSCI.4970-06.2007

Shorter, J., & Lindquist, S. (2005). Prions as adaptive conduits of memory and inheritance. *Nature Reviews Genetics*, *6*(6), 435–450. https://doi.org/10.1038/nrg1616

Sibille, N., Sillen, A., Leroy, A., Wieruszeski, J.-M., Mulloy, B., Landrieu, I., & Lippens, G. (2006). Structural Impact of Heparin Binding to Full-Length Tau As Studied by NMR Spectroscopy †. *Biochemistry*, *45*(41), 12560–12572. https://doi.org/10.1021/bi060964o

Siemers, E. R., Friedrich, S., Dean, R. A., Gonzales, C. R., Farlow, M. R., Paul, S. M., & Demattos, R. B. (2010). Safety and changes in plasma and cerebrospinal fluid amyloid β after a single administration of an amyloid β monoclonal antibody in subjects with Alzheimer disease. *Clinical Neuropharmacology*, *33*(2), 67–73. https://doi.org/10.1097/WNF.0b013e3181cb577a

Sigurdsson, E. M., Knudsen, E., Asuni, A., Fitzer-Attas, C., Sage, D., Quartermain, D., … Wisniewski, T. (2004). An Attenuated Immune Response Is Sufficient to Enhance Cognition in an Alzheimer's Disease Mouse Model Immunized with Amyloid- Derivatives. *Journal of Neuroscience*, *24*(28), 6277–6282. https://doi.org/10.1523/JNEUROSCI.1344-04.2004

Sigurdsson, E. M., Scholtzova, H., Mehta, P. D., Frangione, B., & Wisniewski, T. (2001). Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. *The American Journal of*

Pathology, *159*(2), 439–447. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/11485902

Solfrizzi, V., Logroscino, G., Santamato, A., Greco, A., & Pilotto, A. (n.d.). Immunotherapy for Alzheimer ' s disease : from anti- b - amyloid to tau-based immunization strategies R eview, 213–238.

Solomon, B. (2003). A LZHEIMER ' S T HERAPEUTICS : Anti-Amyloid Immunological Approach for the Treatment of Alzheimer ' s Disease, *20*, 283–286.

Spires-Jones, T. L., de Calignon, A., Matsui, T., Zehr, C., Pitstick, R., Wu, H.-Y., … Hyman, B. T. (2008). In Vivo Imaging Reveals Dissociation between Caspase Activation and Acute Neuronal Death in Tangle-Bearing Neurons. *Journal of Neuroscience*, *28*(4), 862–867. https://doi.org/10.1523/jneurosci.3072-08.2008

Srinivasan, R., Mohankumar, R., Kannappan, A., Karthick Raja, V., Archunan, G., Karutha Pandian, S., … Veera Ravi, A. (2017). Exploring the Anti-quorum Sensing and Antibiofilm Efficacy of Phytol against Serratia marcescens Associated Acute Pyelonephritis Infection in Wistar Rats. *Frontiers in Cellular and Infection Microbiology*, *7*, 498. https://doi.org/10.3389/fcimb.2017.00498

Surin, A. K., Grigorashvili, E. I., Suvorina, M. Y., Selivanova, O. M., & Galzitskaya, O. V. (2016). Determination of Regions Involved in Amyloid Fibril Formation for Ab(1-40) Peptide, *81*(7), 999–1007. https://doi.org/10.1134/S0006297916070130

Surmacz-Chwedoruk, W., Nieznańska, H., Wójcik, S., & Dzwolak, W. (2012). Cross-seeding of fibrils from two types of insulin induces new amyloid strains. *Biochemistry*, *51*(47), 9460–9469. https://doi.org/10.1021/bi301144d

Takashima, A. (2010). TAU Aggregation is a Therapeutic Target for Alzheimers Disease.

Current Alzheimer Research, *7*(8), 665–669. https://doi.org/10.2174/156720510793611600

Tamura, Y., Hamajima, K., Matsui, K., Yanoma, S., Narita, M., Tajima, N., … Okuda, K. (2005). The F(ab′)2 fragment of an Aβ-specific monoclonal antibody reduces Aβ deposits in the brain. *Neurobiology of Disease*, *20*(2), 541–549. https://doi.org/10.1016/j.nbd.2005.04.007

Tariot, P. N., & Aisen, P. S. (2009a). Can Lithium or Valproate Untie Tangles in Alzheimer's Disease? *The Journal of Clinical Psychiatry*, *70*(6), 919–921. https://doi.org/10.4088/JCP.09com05331

Tariot, P. N., & Aisen, P. S. (2009b). Can Lithium or Valproate Untie Tangles in Alzheimer's Disease? *The Journal of Clinical Psychiatry*, *70*(6), 919–921. https://doi.org/10.4088/JCP.09com05331

Taylor, J. D., & Matthews, S. J. (2015). New insight into the molecular control of bacterial functional amyloids. *Frontiers in Cellular and Infection Microbiology*, *5*(April), 1–7. https://doi.org/10.3389/fcimb.2015.00033

Toledo, J. B., Shaw, L. M., & Trojanowski, J. Q. (2013). Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker. *Alzheimer's Research & Therapy*, *5*(2), 8. https://doi.org/10.1186/alzrt162

Torrent, M., Pulido, D., Nogués, M. V., & Boix, E. (2012). Exploring New Biological Functions of Amyloids: Bacteria Cell Agglutination Mediated by Host Protein Aggregation. *PLoS Pathogens*, *8*(11). https://doi.org/10.1371/journal.ppat.1003005

Tracy, T. E., Sohn, P. D., Minami, S. S., Wang, C., Min, S. W., Li, Y., … Gan, L. (2016). Acetylated Tau Obstructs KIBRA-Mediated Signaling in Synaptic Plasticity and

Promotes Tauopathy-Related Memory Loss. *Neuron*, *90*(2), 245–260. https://doi.org/10.1016/j.neuron.2016.03.005

Vasconcelos, B., Stancu, I. C., Buist, A., Bird, M., Wang, P., Vanoosthuyse, A., … Dewachter, I. (2016). Heterotypic seeding of Tau fibrillization by pre-aggregated Abeta provides potent seeds for prion-like seeding and propagation of Tau-pathology in vivo. *Acta Neuropathologica*, *131*(4), 549–569. https://doi.org/10.1007/s00401-015-1525-x

Venegas, C., & Heneka, M. T. (2016). Danger-associated molecular patterns in Alzheimer's disease. *Journal of Leukocyte Biology*, *101*(1), 87–98. https://doi.org/10.1189/jlb.3mr0416-204r

Vescovo, G. (2010). Cardiomiopatia diabetica r t i e ic s i t e, *3*(2), 67–71.

Walsh, D., & Selkoe, D. (2004). Oligomers on the Brain: the Emerging Role of Soluble Protein Aggregates in Neurodegeneration. *Protein & Peptide Letters*, *11*(3), 213–228. https://doi.org/10.2174/0929866043407174

Weiner, H. L., Lemere, C. A., Maron, R., Spooner, E. T., Grenfell, T. J., Mori, C., … Selkoe, D. J. (2000). Nasal administration of amyloid-? peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. *Annals of Neurology*, *48*(4), 567–579. https://doi.org/10.1002/1531-8249(200010)48:4<567::AID-ANA3>3.0.CO;2-W

Weiner, M. W., Aisen, P. S., Jack, C. R., Jagust, W. J., Trojanowski, J. Q., Shaw, L., … Schmidt, M. (2010). The Alzheimer's Disease Neuroimaging Initiative: Progress report and future plans. *Alzheimer's and Dementia*, *6*(3), 202-211.e7. https://doi.org/10.1016/j.jalz.2010.03.007

Wisniewski, T., & Konietzko, U. (2008). Amyloid-beta immunisation for Alzheimer's disease. *The Lancet. Neurology*, *7*(9), 805–811. https://doi.org/10.1016/S1474-

4422(08)70170-4

Wisniewski, T., & Sigurdsson, E. M. (2010). Murine models of Alzheimer's disease and their use in developing immunotherapies. *Biochimica et Biophysica Acta - Molecular Basis of Disease*, *1802*(10), 847–859. https://doi.org/10.1016/j.bbadis.2010.05.004

Wozniak, M. A., Frost, A. L., Preston, C. M., & Itzhaki, R. F. (2011). Antivirals Reduce the Formation of Key Alzheimer's Disease Molecules in Cell Cultures Acutely Infected with Herpes Simplex Virus Type 1. *PLoS ONE*, *6*(10), e25152. https://doi.org/10.1371/journal.pone.0025152

Yamada, K., Yabuki, C., Seubert, P., Schenk, D., Hori, Y., Ohtsuki, S., … Iwatsubo, T. (2009). A Immunotherapy: Intracerebral Sequestration of A by an Anti-A Monoclonal Antibody 266 with High Affinity to Soluble A . *Journal of Neuroscience*, *29*(36), 11393–11398. https://doi.org/10.1523/JNEUROSCI.2021-09.2009

Yu, Y. Z., Wang, W. Bin, Chen, A., Chang, Q., Liu, S., Zhao, M., … Sun, Z. W. (2014). Strikingly reduced amyloid burden and improved behavioral performance in Alzheimer's disease mice immunized with recombinant chimeric vaccines by hexavalent foldable Aβ1-15fused to toxin-derived carrier proteins. *Journal of Alzheimer's Disease*, *41*(1), 243–260. https://doi.org/10.3233/JAD-132177

Zhang, J., Wu, X., Qin, C., Qi, J., Ma, S., Zhang, H., … He, W. (2003). A novel recombinant adeno-associated virus vaccine reduces behavioral impairment and β-amyloid plaques in a mouse model of Alzheimer's disease. *Neurobiology of Disease*, *14*(3), 365–379. https://doi.org/10.1016/j.nbd.2003.07.005